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ABSTRACT
The oral hypoglycemic agent Glyburide has been shown to be actively transported
from various biological tissues though a pronounced interaction with the ATP binding
cassette (ABC) active transport proteins. Specifically, Glyburide is actively
transported by the ABC proteins, P-glycoprotein (Pgp), Breast Cancer Resistance
Protein (BCRP), and the Multidrug Resistance Proteins (MRP). This active transport
occurs at various locations throughout the body but has been identified as being
responsible for Glyburide’s unique placental transport behavior. Glyburide has been
shown to not cross the placental barrier to any appreciable effect and will leave the
placental barrier against the concentration gradient. Understanding this active
transport creates the possibility of medicines designed specifically for pregnant
women. The objective of this thesis is to investigate the activity of Glyburide and a
series of sulfonylurea analogs against these two ABC transporter proteins.
The transport of Glyburide and a series of sulfonylurea analogs in the presence of Pglycoprotein (Pgp) and breast cancer resistance protein (BCRP) was investigated in
cell-based transport assays using two stably transfected Madin-Darby Canine Kidney
cell lines, one overexpressing Pgp and the other overexpressing BCRP genes. The
results of the transport studies confirm that both Pgp and BCRP play a role in the
transport of the sulfonylureas. Further, in addition to Glyburide, the molecules
Glimepiride, Glisoxepide, and Gliquidone were confirmed as Pgp and BCRP
substrates, all of which has not previously been reported.
Subsequently, the sulfonylurea transport activity with both Pgp and BCRP were used
as the basis to build quantitative structure activity relationship (QSAR) and
ii

pharmacophore models. These models suggest that there are core molecular features
necessary for the Pgp and BCRP activity, specifically that the arylsulfonylurea and
benzamido ligands are required for both activities. We also found that increased
hydrophobic character and increased bulky groups are key to both activities. The main
differences in the activities were surrounding the sulfonylurea and amide moieties,
with positive charge increasing the BCRP activity, and negative charge increasing the
Pgp activity. Overall, the results of this research serve to provide improved knowledge
for the design of pregnancy centered medications.
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INTRODUCTION

Glyburide (generic, glibenclamide) is a small molecule sulfonylurea used for the
treatment of hyperglycemia. Glyburide is the most prescribed small molecule for the
first line of defense or the treatment of Type II Diabetes due to its very attractive
pharmacological profile.1 The sulfonylurea compounds were first discovered by Janbon
et al.; when researching sulfonamides in patients with typhoid fever, the team noted
hypoglycemic results, leading to introduction of sulfonylureas to treat hyperglycemia
into the US commercial market in 1955. 2 The sulfonylureas have evolved over two
generations, though each generation shares the same core sulfonylurea backbone as
presented in Figure 1.

Figure 1. Sulfonylurea backbone.

Sulfonylureas development has been sixty years in the making, with the first-generation
molecules developed in 1950-1980’s, and the second-generation molecules developed
during the 1980-1990’s. The two generations of sulfonylureas differ in the physicalchemical attributes, and subsequent pharmacokinetic/pharmacodynamic (PK/PD)
parameters, with the latter generation having an increased safety and efficacy. 3 The
improvements to the physical-chemical and PK/PD parameters are due to the structural
changes at the para position on the central aryl ring (R1) and functional group R2
attached to the remote urea position, as detailed in Figure 1. The first-generation
2

sulfonylureas have smaller molecular weights, with more polar and hydrophilic
substituents. The second-generation sulfonylureas have larger molecular weights,
containing more non-polar lipophilic substituents. This increased lipophilic character
allows for easier membrane permeability, and therefore an increased potency. This is an
important point to discuss as the target protein, the sulfonylurea receptor (SUR1), is
membrane bound protein, and having molecules with an increased hydrophobicity
allows for the molecules to penetrate the membrane more readily, reaching the receptor
more efficiently. 4 The commercial sulfonylurea structures are presented in Figures 2
and 3.

Tolbutamide

Metahexamide

Glibornuride

Acetohexamide

Chlorpropamide

Tolazamide

Glyclopyramide

Carbutamide

Gliclazide

Figure 2. Representative structures of the first-generation sulfonylurea hypoglycemic
agents.
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Glimepiride

Glyburide

Gliquidone

Glipizide

Glisoxepide

Figure 3. Representative structures of the second-generation sulfonylurea hypoglycemic
agents.

As expected, the similarity of the core structure of the first and second-generation
sulfonylureas allow for a similar response to reducing hyperglycemia. 5 This can be
explained in the structure activity relationship research performed for the development
of the sulfonylureas, as demonstrated by an increase in binding affinity for the
sulfonylurea receptor 1 (SUR1). The SUR1 receptor is an active transporter that has
been shown to have multiple binding sites, A and B, with the more potent secondgeneration molecules believed to bind to both the A and B sites. For reference, the
molecules tolbutamide (1st gen) and glyburide (2nd gen) and the representative binding
sites of SUR1 are presented in Figure 4. 6 This increased structure activity relationship
(SAR) work also presents as a longer half-life, higher lipophilicity, and increased plasma
protein binding adding to the increase in efficacy and safety. 7
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Figure 4. Biding Site of SUR1 protein and 1st and 2nd generation SUs structural map.8

SULFONYLUREAS FOR TYPE II DIABETES
The sulfonylurea chemical class has been widely used in the treatment of hyperglycemia
for more than sixty years and is now a popular choice for a first line of treatment in
diabetes care. Specifically, the sulfonylureas have become an integral treatment option
for those patients who have not maintained or achieved adequate glycemic control
through diet and exercise alone. 9, 10, 11 The sulfonylureas work by binding to the SUR1
receptor, which triggers the cascade of two signal pathways that release insulin in the
pancreatic β-cell. The first pathway is the ATP-sensitive potassium channel (KATP)
pathway and is the link between glucose metabolism and the stimulation of insulin
production. The second pathway is a glucose signaling pathway and augments the
insulin release due to the increase in the Ca2+ concentration. 12 In this respect, the
sulfonylureas are insulin secratogues, meaning that the mode of action is similar to that
of insulin, stimulating the ATP sensitive Potassium (KATP) channels within the
pancreatic β- cells. 13 In summary, this action stimulates the insulin release via the
occupation of the β-cell membrane SUR1. 14, 15, 16 In response to an increase in blood
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glucose concentrations, the enhanced rate of glucose metabolism causes the changes in
concentrations of the adenosine diphosphate (ADP) and adenosine triphosphate (ATP),
driving the closure of the pore. The depolarization of the cell membrane is due to a
decrease in the K+ permeability into the cell and an opening of the Ca2+ channels. This
enhancement of the Ca+2 influx across the cell membrane is the final step of the cascade
and triggers the release of insulin. 17 The dual pathway mechanism of insulin release in
the pancreatic beta cells is depicted in Figure 5.

Figure 5. The mechanism of glucose dependent insulin release in pancreatic β- cells. 18

SIMILARITIES BETWEEN T2D AND GESTATIONAL DIABETES MELLITUS
STATES
As part of normal function, the body needs to regulate insulin production as a direct
response to the increase or decrease in blood sugar levels after food consumption. There
are two states of blood sugar levels, hyperglycemia and hypoglycemia, which represent
too much and too little blood sure, respectively. Hyperglycemia can be a chronic
6

condition in which the body’s inability to produce any or enough insulin causes elevated
levels of glucose in the blood, and are known as Type I and Type II Diabetes,
respectively. 19 Both types of Diabetes are characterized by an insulin resistance and a
resultant insulin deficiency. In general terms, Type I diabetes is an autoimmune disorder
leading to the destruction of pancreatic beta cells and hence the body’s inability to
produce insulin; and Type II Diabetes is primarily a problem of progressively impaired
glucose regulation due to the dysfunction of the pancreatic beta cells and general insulin
resistance.20, 21 . Also, Type II diabetes is influenced by many genetic and environmental
factors, such as obesity and overweight contributing to the insulin resistance,
compounding the issue. 22 Researchers have found that the occurrence rate of Type 1 vs
Type 2 Diabetes is approximately 10% and 90%, respectively, regardless of country or
population. 23
Type I diabetes has only one treatment option, daily injections of insulin to directly
manage blood sugar levels. Type II diabetes, however, has multiple treatment options
available, including diet, exercise, pharmacological treatment, or a mix of all three. The
bulk of the Type II case are treatable with diet and exercise changes alone, with only
approximately 30% of Type II patients requiring pharmacological treatment. 24
This inability to control blood glucose levels occurs in pregnant women and is referred
to as pregnancy induced gestational diabetes mellitus (GDM). The definition of GDM is
carbohydrate intolerance resulting in hyperglycemia, with the onset or recognition
occurring during pregnancy. 25 GDM is a well characterized disease affecting a large
portion of the population and has been widely linked to the weight gain associated with
pregnancy. 26 Although the exact cause of GDM is not known, there are some theories
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that may explain the condition and why it occurs. During pregnancy, the placenta
supplies the fetus with nutrient and water, and produces hormones to maintain the
pregnancy throughout gestation. Some of these hormones produces a contra-insulin
effect, blocking the normal function of insulin. As the gestational period goes on, the
placenta grows, produces more hormones, and the increase of insulin resistance becomes
greater. Under normal circumstances, and normal pancreatic function, there would
simply be an increase in insulin production to compensate for the state of insulin
resistance. However, when the production of insulin is somehow blocked by the effect
of the placental hormones, GDM can occur. GDM occurs in up to 20% of all pregnancy
globally, depending on country, population demographic and lifestyle, though
approximately 30-40% requiring pharmacological treatment. 27, 28, 29, 30
Type II and GDM are characterized by insulin resistance and a subsequent insulin
deficiency, and numerous studies have demonstrated that the rate of occurrence within a
population of GDM to Type II Diabetes are similar. 31 However, the one real difference
between Type II and GDM is that pregnancy is a state of increasing insulin resistance, as
the need to provide a constant supply of nutrients to the fetus. This pathological increase
in insulin resistance, diminished sensitivity and impaired insulin secretion due to various
conditions of pregnancy, which runs counter to the need of the developing fetus and
produces a serious condition of hyperglycemia in the mother. 32 So, the goal of any
Diabetes-related management during pregnancy is to maintain blood glucose as close to
normal as possible.

8

CHALLENGES OF GDM TREATMENT TO MOTHER AND FETUS
As noted, GDM occurs in a significant number of pregnancies globally, and is
considered a risk factor for Type II Diabetes for the mother. There is a great deal of
evidence that proves the treatment of GDM is far better than not treating GDM. In fact,
common conditions are drastically reduced through treatment options, saving the mother
and fetus from hypertension, preeclampsia, urinary tract infections, development of
Type II diabetes later in life in mothers and child, as well as macrosomia, neonatal
hypoglycemia, and childhood obesity. 33 Leaving these conditions untreated will
potentially cause harm to the mother and fetus, and requires chronic maintenance
through proper diet, exercise and pharmacological treatment. 34
Therefore, to be a successful medication for GDM, the need to control blood glucose in
a similar manner to insulin, while maintaining the safety of the mother and fetus
paramount. Prescribing drugs in pregnancy represents an unusual situation that must be
constantly monitored. Drugs that will help the mother can deform or kill the fetus. 35
This is well characterized that there are a small group of drugs that are known to cause
adverse events or birth defects in humans, but the safety or harm to the fetus must not be
exaggerated. Today, the importance of monitoring the pregnant woman and fetus for
harm is well understood, but initially, the placenta was thought to be a barrier, protecting
the fetus from harm and the mother’s blood, and delivering only what’s needed, for
example essential nutrients. The Thalidomide disaster of the 1950’s demonstrated that
the placenta was a very leaky barrier, and that precautions must be taken when treating
pregnant women with medicines, as it is now understood that many substances will cross
the placenta. 36 Treatment conditions of the mother quickly accounts for how much harm
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will be done to the fetus, and that can be determined by the rate and extent of the of the
drug concentration that crosses the placenta, and at what gestational stage. 37
For those patients that cannot manage the hyperglycemia with diet and exercise alone,
the preferred pharmacological treatment option for diabetes has been insulin. The same
approach is taken for GDM, with insulin as the first line of treatment due to its high
efficacy, safety, and the fact that the higher molecular weight insulin cannot cross the
placenta barrier. 38, 39 Insulin treatment however, suffers from compliance issues and in
some countries the cost is prohibitive. 40 Specific to pregnant women, the insulin route
of administration and the schedule of treatments present numerous difficulties.41 Due to
the similarities in GDM and Type II conditions, and the ease of treatment for oral
medications, doctors have explored treating GDM with the small molecule
sulfonylureas. 42, 43
In order for the sulfonylureas to be effective in the treatment of diabetes, the patient
needs to have retained some level of pancreatic insulin-releasing function. 44 This holds
true for GDM based on the similarities of the pathophysiology with Type II, the
sulfonylurea compounds are an excellent choice for treating either condition. 45,46 In fact,
there is a growing acceptance of Glyburide as a treatment option for GDM, based on the
attractive pharmacological response and low potential adverse side effects (i.e., neonatal
hypoglycemia), making the sulfonylurea(s) a viable option based on compliance, and
overall mother and fetal outcomes. 47,48, 49
Considerable data exists suggesting that Glyburide is a safe alternative to insulin for
treatment of GDM. 50 Numerous clinical studies, and five retrospective studies, have
been performed on thousands of pregnant women who were taking Glyburide. These
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studies have been performed to understand the pharmacokinetics and
pharmacodynamics of Glyburide during pregnancy, and many interesting results have
been demonstrated. In these multiple, large, randomly controlled clinical studies,
Glyburide has been shown to be as safe and effective as insulin in pregnant women. 51, 52,
53, 54, 55

Further, placental drug transport studies have demonstrated two key findings:

Glyburide does not cross the placenta to any appreciable extent, and Glyburide will
leave the placental barrier against the concentration gradient. 56, 57, 58, 59, 60 This represents
an ideal situation for treating pregnant women and has garnered much excitement.

TRANSPORTER STORY
The placental transport studies have demonstrated that Glyburide is a substrate for active
transport by the ATP Binding Cassette (ABC) transporter proteins specifically Pglycoprotein (Pgp), Breast Cancer Resistance Protein (BCRP), and the Multiple
Resistance Protein (MRP) family. 61, 62,63, 64, 65 The ABC transporter proteins are part of
a larger class of drug transporters, with a primary function to transport nutrients and
endogenous substrates (sugars, amino acids, vitamins), and to protect the body from
dietary and environmental toxins. 66 As the transporters are designed to transport
substrates of a wide physiologic background, drugs that are similar in structure to the
physiological substrate can also be transported. It is in this functionality and the ability
to transport a broad range of substrates that the drug transporters play a significant role
in the bioavailability, efficacy and PK of most drugs. 67
Transport of drugs can be classified in a variety of ways, with the main characterizations
being directional (efflux vs influx), and through energy vs non-energy dependent (active
11

or passive) means. For the context of the work reported here, we will focus on the efflux
by active transport systems, which have been further classified into two main categories,
primary and secondary. The primary systems utilize ATP hydrolysis to drive the
transport and include the ABC transporters. The secondary systems are ones that utilize
multiple driving forces such as ion concertation gradients, and electric potential
difference across the cell membrane, an example is the Solute Carrier transporters
(SLC). 68, 69
The ABC proteins of the human genome comprise a family of 49 proteins, and based on
their amino acid sequence, are divided into roughly 7 sub-families. As ABC
transporters serve a protection function, they are found in most tissues at barrier
locations throughout the body, such as brain, testes, heart, liver, kidney, and
gastrointestinal tract. Transporter proteins are membrane-bound proteins whose primary
function is to facilitate the flux of molecules in and out of cells, protecting from toxins.
70,71, 72

The ABC drug transporters have a diverse substrate pool; as such, many

molecules that bear structural similarities to the endogenous compounds may be
recognized and transported. This diverse set of substrates covers molecules that are
nonpolar, weakly amphiphilic, and encompass a diverse group of compounds from anticancer drugs to natural products. 73, 74, 75
As illustrated in Figure 4, all ABC Transporter proteins share similar structural
components, consisting of 4 different domains: two transmembrane and two cytosolic
domains. The transmembrane domains (TMD) consist of alpha helices (in groups of 5-6)
embedded in the membrane bilayer, with the ability to recognize and transport a broad
range of substrates by changing conformations. The nucleoside binding domains (NBD)
12

is the location of the binding of ATP that drives the transport mechanism, containing the
Walker A and B motifs for this function. 76 A complete transporter structure is
considered a homo-dimer or a fully functional transporter, example of which are Pgp,
MRP, and OATP. The exception to this requires the two smaller monomer structures to
pair together to form a homodimer, an example of this is BCRP.

Figure 6. Structures of two categories of ABC transporters, Pgp (ABCB1-MDR1) and
MRPs are shown on top, BCRP (ABCG2) shown on bottom. 77

PROBLEM STATEMENT AND SUMMARY OF REMAINING SECTIONS OF
THESIS
The ABC transporters described above in Figure 6 hold the key to the unique placental
transport of Glyburide. As discussed, the oral hypoglycemic sulfonylurea molecule
Glyburide has been shown to be actively transported through a pronounced interaction
with the ATP binding cassette (ABC) active transporter proteins. This unique placental
transport behavior is largely due to the primary transport resulting in the efflux of
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Glyburide by Pgp and BCRP, minimizing the effect of the drug on the fetus.
Specifically, the small molecule Glyburide has been shown to not cross the placental
barrier to any appreciable effect; and, Glyburide will leave the fetal compartment against
the concentration gradient (active efflux). 78 The research presented here will focus on
understanding this unique placental transport to design medications for pregnant women
that are safe and effective, without presenting harm to the mother or fetus.
There is a great deal of research detailing the mechanism of action of the sulfonylureas,
the PK/PD of the sulfonylureas during pregnancy, and even the specific ABC transporter
proteins responsible for the unique placental transport behavior. However, there has
been no research to date to explain the nature of the interaction with the ABC transporter
proteins to better design pregnancy centered drugs. The research presented here will
look to explain the interactions of a series of sulfonylurea analogs and two of the main
ABC proteins responsible for active drug transport, BCRP and Pgp. The work described
in this body of work was performed in cell-based transport assays using cell lines that
overexpress Pgp or BCRP, and molecular modeling software packages to build structure
activity models based on the transport activity.
In the coming chapters we will explore the interaction of the sulfonylureas with the two
transporters, individually, building quantitative structure activity relationships (QSAR),
and then complete the body of work with molecular modeling highlighting the molecular
descriptors/features that drive the affinity to one transporter or the other. In Chapter 2
we will evaluate the sulfonylurea analogs using Madin-Darby Kidney Cells (MDCK)
that overexpress Pgp and BCRP proteins, ultimately building 2D, 3D-QSAR and
pharmacophore models using the molecular dynamics modeling software VLifeMDS®
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to explain the molecule-protein interaction. And finally, in Chapter 3, we will detail and
explain the similarities and differences between the two molecule-protein interactions,
using the molecular modeling software Cresset Group Forge®. The outcome of this
research will be to characterize the molecular features driving the interactions with the
ABC transporter proteins, in the hope that this knowledge will help design novel
pregnancy centered medications.
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Quantitative Structure Activity Relationship for a Series of Sulfonylurea Analogs
and two ATP Binding Cassette Proteins, P-glycoprotein and Breast Cancer
Resistance Protein

ABSTRACT
Sulfonylureas used in the treatment of Type II diabetes have been shown to interact with
the ATP binding cassette (ABC) active transporters, P-glycoprotein (Pgp) and Breast
Cancer Resistance Protein (BCRP). Starting from a series of sulfonylurea compounds,
two and three-dimensional quantitative structure activity relationship (QSAR) studies
were performed to determine the essential molecular features responsible for the Pgp and
BCRP mediated transport. For the both the 2D and 3D QSARs, numerous models were
developed and evaluated in an effort to correlate the physico-chemical features of the
sulfonylureas with the biological interaction with Pgp or BCRP. In our studies, the 2D
Pgp QSAR model with the best prediction capability was found to be a k-Nearest
Neighbor (kNN) model for substrate activity with a q2 = 0.7152, and a r2 = 0.8150. For
the 3D Pgp QSAR model with the best prediction capability, a multiple regression model
for substrate activity performed best, with an r2 = 0.8304, a cross-validation q2 = 0.7501.
In contrast, the 2D BCRP QSAR model with the best prediction capability was a multiple
linear regression (MLR) model for substrate activity with a q2 = 0.8690, and a r2 =
0.8131. Similarly, the 3D BCRP QSAR model with the best prediction capability was a
multiple regression model for substrate activity with an r2 = 0.9063, a cross-validation q2
= 0.7789. All models were cross validated with an autonomous set of compounds not
used in the training or test sets.
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As previously reported, Glyburide has been shown to be a substrate for numerous ABC
transporters, but this is the first comprehensive QSAR study designed to understand the
interaction driving the active transport of the entire class of sulfonylureas specifically
with the two ABC transporters, Pgp and BCRP. The physico-chemical properties and
molecular descriptors of the sulfonylureas were used to build three-dimensional
pharmacophores to further understand the interactions with Pgp and BCRP. Each
pharmacophore model contained five features found to be essential for identification as a
Pgp or BCRP substrate: one hydrogen bond donor, two hydrogen bond acceptors, and
two aromatic rings. For both Pgp and BCRP pharmacophores, the active sites focused on
the benzamido and arylsulfonylurea ligands. However, the two pharmacophore models
differed in the location of the fifth active site, with Pgp activity needing an unsubstituted,
and the BCRP activity needing the substituted, benzamido ligand. This work confirms
Glyburide as a substrate for both Pgp and BCRP, and details the oral hypoglycemic
agents Glimepiride, Glisoxepide, and Gliquidone as Pgp substrates; with Glimepiride and
Glisoxepide confirmed as BCRP substrates not previously reported.

INTRODUCTION
The oral hypoglycemic sulfonylurea molecule Glyburide has been shown to be actively
transported from various biological tissues though a pronounced interaction with the ATP
binding cassette (ABC) active transporter proteins.

79, 80, 81, 82, 83, 84, 85

Specifically,

Glyburide is actively transported by the ABC proteins, P-glycoprotein (Pgp), Breast
Cancer Resistance Protein (BCRP), and the Multidrug Resistance Proteins (MRP). 86, 87
This active transport occurs at various locations throughout the body but has been
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identified as responsible for unique transport behavior of Glyburide at the placenta
barrier. Glyburide has been shown to not cross the placental barrier to any appreciable
effect, and will leave the placental barrier against the concentration gradient, attributed to
the active transport by the ABC proteins. Harnessing the unique placental transfer by the
ABC proteins and understanding what molecular features drive the drug-protein
interaction, creates the possibility of designing medications specifically for pregnant
women. Glyburide is a second-generation sulfonylurea hypoglycemic agent, widely used
in the treatment of Type II diabetes. 88, 89, 90 The sulfonylurea molecule class are insulin
secratogues, stimulating the ATP sensitive Potassium (KATP) channels within the
pancreatic β-islet cells. 91 Stimulation of the KATP channel triggers the insulin release via
the occupation of the ABC sulfonylurea receptor (SUR1) in the β-cell membrane. 92, 93 In
order for this mechanism to work, patients need to have retained some level of pancreatic
β-cell function, as shown in the cascade of events presented in Figure 7.

Figure 7. Modulation of insulin, reproduced from Tahrani et al. 94
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In general terms, Type II Diabetes is primarily a condition of progressively impaired
glucose regulation due to the dysfunction of the pancreatic beta cells and general insulin
resistance. 15, 95 This impaired glucose regulation can also occur in pregnant women and
is commonly referred to as pregnancy induced gestational diabetes mellitus (GDM).
GDM occurs in up to 20% of all pregnancy globally, with approximately 90% of those
diagnosed as treatable Type II diabetes, and roughly 30-40% requiring pharmacological
treatment. 4, 96, 97, 98

Figure 8. Structures of the Glyburide and the sulfonylurea backbone.

For both Type II and GDM, insulin has been the gold standard of treatment; however,
with the availability and ease of treatment of oral hypoglycemic medications, doctors
have recently attempted to treat GDM with small molecule therapeutics. 99, 100, 101 The
similarities of the pathophysiology of both the Type II and GDM indicate that the oral
hypoglycemic sulfonylureas are appropriate, and numerous studies have been performed
to understand the pharmacokinetics and pharmacodynamics of Glyburide during
pregnancy. 1, 16 In multiple clinical studies, Glyburide has been shown to be as safe and
effective as insulin in pregnant women. 102, 103, 104, 105, 106 Further, studies evaluating the
fetal pharmacokinetics of Glyburide have demonstrated two remarkable findings: that
Glyburide does not cross the placenta to any appreciable extent as compared to other
20

sulfonylureas (Glyburide 3.9%, Glipizide 6.6%, Tolbutamide 21.5%, and
Chlorpropamide 11%) and Glyburide will leave the placenta barrier against the
concentration gradient.107 As previously mentioned, this unique placental transport
behavior has been demonstrated to be ABC transporter mediated. Evaluation of this
unique transport has been performed in vitro, and repeatedly demonstrated in cell lines
and in placenta-like models (vesicles, perfused placenta, etc.), confirming Glyburide as a
substrate for active transport, and demonstrating that the mechanism of placenta transport
can be studied in vitro.108, 109, 110,111
Understanding the sulfonylurea and ABC transporter interactions and the unique
placental transport serves as an example for the design of pregnancy center drugs. To
further investigate this unique interaction of the sulfonylureas with the ABC transporter
proteins, Glyburide and a series of sulfonylurea analogs were tested in in vitro cell-based
transport assays using a Madin-Darby kidney cell (MDCK) lines overexpressing either
the Pgp or BCRP proteins. From the measured transporter activity, we developed both 2D
and 3D quantitative structure activity relationship (QSAR) models to account for the Pgp
and BCRP substrate activity for the sulfonylurea compounds. To accompany this work,
we have performed a two-step computational study to generate the 3D pharmacophore to
aid in describing the parts of the molecule responsible for the Pgp and/or BCRP activity.

MATERIALS and METHODS
A set of 78 sulfonylurea compounds were acquired for this study, selected via a
compound similarity search against Glyburide in both the Pfizer internal and publicly
available external databases. The compounds for the study were further selected based on
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the Tanimoto searching criteria of >70% similarity, which allowed for the selection of
molecules based on the structural similarities to Glyburide. The sulfonylurea analogs
were divided into two groups, the commercial sulfonylureas (molecules 1-14) and the
sulfonylurea analog series (molecules 15-78). The structures of all molecules studied are
presented in Appendix I and II.

CELL CULTURES
The Madin-Darby Canine Kidney cell line stably transfected with the Pgp gene (MDCKMDR) or the BCRP gene (MDCK-BCRP) were used in the present study and have been
thoroughly characterized. 112,113, 114 The MDCK-MDR cells were initially received from
Pier Borst and the National Cancer Institute (NCI), Netherlands, and maintained by the
PDM labs, Pfizer Global Research and Development, Groton, CT. 115, 116, 117, 118 The
MDCK-BCRP cell line are a stably transfected cell line, developed and maintained at the
Pfizer PDM labs Groton CT. 119 Briefly, the stably transfected MDCK-MDR or MDCKBCRP cells were cultured in Dulbecco’s minimum essential media (MEM) with
supplements, in 75cm2 tissue culture T-flasks were incubated at 37°C with 95% and 5%
CO2 and passaged every 4 days after achieving 90% confluence. The cells were then
harvested with trypsin and plated for a density of 2 x 106 cells/cm in Falcon/BD 96 well
insert plates with a 1µm pore polyethylene terephthalate filter. Seeded inserts were then
placed into prefilled Falcon/BD feeder trays containing 37mL growth medium and
incubated at 37°C with 95% and 5% CO2 for 4 days. Immediately prior to performing the
assay, each well of the plates were assessed for uniform barrier functionality of the
polarized cell monolayers. The integrity of the MDCK-MDR or MDCK-BCRP cell
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monolayers were evaluated by measuring the trans-epithelial electrical resistance, and
only those cell monolayers with a measurement with of at least 320Ωcm2 were used.120

TRANSPORT ASSAY PROCEDURES
The cell transport assays are the most direct assay for performing drug transfer studies
across a cell monolayer, and to determine a transporters function. The transport assays
have been standardized in that the cell lines are widely shared between research labs or
are commercially available. All transport assays were performed as per standard
procedures, and as previously described. 121,122, 123, 124 Briefly, the assays were performed
in Hanks’ balanced salt solution with 10mM HEPES and 25mM D-glucose, 1.25mM
CaCl2, and 0.5mM MgCl2 at pH 7.4. Assays were performed with set drug concentrations
(2-100µM) and performed in triplicate to generate statistically sound data. Transport
studies were performed by adding the compounds pre-dissolved in dimethyl sulfoxide
(DMSO)/transport buffer to the donor wells and measuring the appearance of drug in the
receiver wells after 2.5 hours at 37°C. For all of the transport studies performed, the drug
was added to the donor compartment A, or the apical side. And the analysis was
completed by measuring the compartment A concentration against the receiver
compartment B, or the basolateral side. Figure 9 depicts an example insert and transport
directions used in the present study.
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Figure 9. Typical cell monolayer setup for Pgp and BCRP assays.

LC-MS ANALYSIS
The LC-MS analysis was conducted according to internal procedures, and as previously
described by L. Di et al, Feng et al, and Varma et al.

125, 126 ,127

Briefly, samples of 25µL

were injected on a Sciex API-5500-Electrospray LC system comprising an Optimize
Technologies SP Small Molecule Trap column, an Apricot/Sounds Analytics ADDA
autosampler, Jackso PU-1580 HPLC pump, and a quadrapole MS detector using the
multiple reaction monitoring (MRM) detection mode. Mobile phase A was 95% 2mM
ammonium acetate/5% 50/50 acetonitrile/methanol and mobile phase B was 90% 50/50
acetonitrile/methanol/ 10% 2 mM ammonium acetate, at a flow rate of 1.5mL/min. The
AUC was integrated using Analyst 1.5.1/DiscoveryQuantAnalyze software, version
2.1.0.14 and compared to standards for each compound in cell culture media for the
quantification of concentrations.

DATA ANALYSIS
For these studies, the apparent permeability (Papp) was calculated for each compound
according to equation 1:
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Equation 1

Where the area is the surface area of the cell monolayer (0.625cm2), CD (0) is the
concentration of compound in the donor chamber, t is the time, Mt is the mass of the
compound, and

is the flux of compound across the cell monolayer. The Papp was

calculated in both apical to basolateral and basolateral to apical directions to determine
the efflux ratio as shown in Equation 2.

Equation 2

where A→B and B→A denote the direction of transport. In order for a compound to be
characterized as a Pgp substrate, the value of the efflux ratio (ER) would exceed a value
of 2.5. The value of 2.5 was determined through internal data analysis and has been
demonstrated to minimize the false-positive and false-negative results in the assay as
tested by the appropriate internal control molecules for each cell line. The efflux ratio is a
way to rank order and predict ABC transporter activity, with the larger efflux ratio
meaning substrate activity.

CELL ASSAY MATERIALS
The 14 commercial sulfonylureas (molecules 1-14 in Appendix 1) were purchased from
Sigma Aldrich, WI, or donated from Pfizer Global R&D, Groton CT. The sulfonylurea
analogs (molecules 15-78 in Appendix I and II) were donated from Pfizer Global R&D,
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Groton CT. Cell culture media reagents, transport buffer (including Hanks balanced salt
solution, HEPES, d-glucose, 1.25mM CaCl2 and 0.5mM MgCl2) were purchased from
Invitrogen, Carlsbad CA. All organic solvents were purchased from Sigma Aldrich, WI
and used as is.

COMPUTER MODELING
All computational studies were performed on an HP, Intel i5 processor running Windows
7 Professional Office, with VLifeMDS® software (version 4.6). 128 In order to minimize
variability and difficulty interpreting the results, it is important to establish a statistically
significant correlation between the molecular descriptors and the biological activity. This
correlation starts with the molecular alignment of the molecules across the test, training,
and validation data sets. 129 Due to the well documented Glyburide ABC substrate
activity, and the common sulfonylurea backbone of the molecules in the present study,
Glyburide was used as the template molecule.
As the x-ray crystal structures of the compounds or the ABC transporter proteins were
not available, the 2D structures were obtained from Chemaxon® Marvin Sketch and
ChemDraw® 15.1. 130, 131 The sulfonylurea molecules are all flexible with many rotatable
bonds which required energy minimization prior to modeling. The minimization was
carried out in the ChemDraw® 3D 15.1 suite utilizing the Merck Molecular force field
(MMFF94). 132, 133, 134, 135 The energy minimizations were carried out using 1000
iterations to eliminate any change in conformations. The RMS gradient was set to 0.100,
the dielectric constant was set to 1.0 and exact calculation, and the Van der Waals
calculation was set to exact. To maximize the modeling, 1000 calculations were

26

performed to eliminate any variability in the lowest energy conformations. The RMS and
van der Waals calculations are parameters that can be adjusted to enhance the threshold
interactions. For our modeling efforts described here, the RMS and van der Waals
parameters were left as recommended by the software. The Figure 4 shows the overlay of
the MMFF94 energy minimized molecules.
The total energy of the molecular conformation was calculated using the MMFF94
relationship presented in Equation 3:

Etotal = EB + EA + EBA + EOOP + ET + EvdW + Eelec

Equation 3

where,
EB = bond stretching energy
EA = angle bending energy
EBA = bond stretching and angle bending energy
EOOP = out of plane bending energy
ET = torsion energy
EvdW = van der Waals energy
EELEC = electrostatic energy

As shown in the energy equation, the MMFF94 energy calculation has multiple energy
terms to capture all potential molecular motions. The total energy of the system is
calculated as the sum of individual energy terms defined for a force field. 136
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Figure 10. Molecular Overlay of MMFF94 energy minimized molecules.

After energy minimization, the molecules were loaded into the VLifeMDS® software
and aligned to a set conformation using the VLifeEngine® module. To correctly overlay
the molecules for quality QSAR modeling, the alignment was performed using the
modules’ atom-based approach. This approach allowed for the selection of the central
arylsulfonylurea section of the Glyburide template molecule. Figure 9 depicts the
molecule overlay of the energy minimized molecules, with Figure 11 showing the
sulfonylurea backbone chosen for molecule conformer alignment template (highlighted in
red).

Figure 11. Glyburide molecule with the sulfonylurea backbone template (highlighted in
red).
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As mentioned previously, with not all crystal structures of the compounds available, the
lowest energy conformations were calculated for each compound using ChemDraw®
15.1. Yuriev et al evaluated previous glyburide structure analysis and modeled glyburide
to determine the three-relevant energy minimized structures - crystal, in vacuo, and in
solution. 137 Previous work L. Lin et al, S.R. Byrn et al, W. Grell et al, and T.J. Hou
explain the various Glyburide energy minimization work in detail. 138, 139, 140, 141 In
summary, the Glyburide SD file was loaded into ChemDraw, and the MMFF94 energy
minimization calculations were performed as described. The Lin et al published lowest
energy confirmations for Glyburide in solution was chosen as the most representative
conformation for our studies.
These findings demonstrate the viability of energy minimization modeling in absence of
crystal structures. The MMFF94 energy minimization for the sulfonylurea analogs
matched the Lin low energy solution model very closely and was used in the present
study, as presented in Figure 12. Future work will evaluate different energy
minimizations and docking, and how that influences the QSAR modeling.

Figure 12. Energy minimized MMFF94 structure of Glyburide.
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EXPERIMENTAL
The experimental work was divided into two main sections, (1) assessing the commercial
sulfonylureas as Pgp or BCRP substrates, and (2) then screening a large series of analogs
for activity to better understand the molecular features responsible for the Pgp or BCRP
activity. The initial experiments were designed to determine if any of the 14 commercial
sulfonylureas (shown in Figure 1) demonstrated Pgp or BCRP activity, and to what
extent. The second set of experiments reported here was designed to determine the two
and three dimensional molecular descriptors of a series of sulfonylurea analogs
responsible for the Pgp or BCRP transporter activity. The molecular descriptors are
described in Appendix IV.
The initial evaluation of the commercial sulfonylureas was run at a standard
concentration, and all compounds were run in at least triplicate. Traditionally, transport
assays evaluating the sulfonylureas have been performed with concentrations ranging
from 1-500µM, depending on the substrate or inhibitor function.142 Accounting for this
range, our studies were performed at a nominal concentration of 2 µM for the
sulfonylurea analogs due to ease of screening and to not saturate the transport mechanism
for Pgp or BCRP activity. Also, to make sure our cell monolayers were performing as
expected, compounds with well documented Pgp or BCRP activity were used as the
controls. The negative control was the molecule antipyrine, which demonstrates unilateral
crossing of the MDCK-MDR and MDCK-BCRP cell monolayers (antipyrine efflux ratio
= 0.99); the positive control for the MDCK-MDR cells was vinblastine which is a welldocumented substrate/inhibitor of Pgp (vinblastine efflux ratio =6.42); and the positive
control for the MDCK-BCRP cells was novobiocin which is a well-documented
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substrate/inhibitor of Pgp (novobiocin efflux ratio =8.65). From this group of commercial
sulfonylureas, four molecules demonstrated high Pgp substrate activity (Glyburide,
Glimepiride, Glisoxepide, and Gliquidone), and one molecule was borderline (Glipizide).
Only three of these molecules demonstrated BCRP substrate activity (Glyburide,
Glimepiride, and Glisoxepide). These molecules are similar to Glyburide, and are also
second-generation sulfonylureas, exhibiting a better safety profile, increased potency, and
higher binding affinity to the Sulfonylurea 1 (SUR1) protein. 143
Having determined the Pgp activity of the commercial sulfonylureas, the next step of the
evaluation was to test the various concentrations of the four compounds to confirm Pgp
activity as a function of the concentration. Glyburide, Glimepiride, Glisoxepide, and
Gliquidone were dosed over a concentration range of 2-100 µM. As Glipizide did not
show Pgp activity in the initial screening study, it was not included in the second round
of testing. Compared to therapeutic doses of Glyburide of approximately 0.202 µM, this
concentration range represents an approximately 10-500 times increase in concentration
and is used to ensure a reproducible measurement. All four compounds demonstrated an
asymmetric transport across the concentration range, with the absorption of each
compound increased with concentration, whereas the efflux slightly increased with
increasing concentrations. Figure 13 depicts the asymmetric relationship of Glyburide,
Glimepiride, Glisoxepide, and Gliquidone.

31

Figure 13. Bar graphs showing asymmetric absorption and efflux of Glyburide,
Glimepiride, Gliquidone, and Glisoxepide. Note: A denotes A-B transport; B denotes B-A
transport.

As shown in the bar graphs of Figure 13, the lower concentrations of the compounds
demonstrated the active transport out of the cells from the basolateral to apical. In the
lower concentration ranges (2-20 µM) the rate of efflux exceeded the rate of absorption
by the following values: approximately 6-8 times for Glyburide, 5-6 times for
Glimepiride, 3-4 times for Gliquidone, and 5-7 times for Glisoxepide. At the highest
concentration tested (100µM), the transport was nonlinear, and the transport started to
balance out, especially for the Glyburide assay. This is an effect of the inhibitory nature
of the compounds at the 100µM concentration, as discussed in literature. 144 These
findings demonstrate the transport is a carrier mediated process from the basolateral to
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apical compartment for each of the compounds represented. These results were expected
based on the known Pgp-Glyburide interaction, and the molecular similarities of the four
compounds. Also, the non-Pgp activity of Gliclazide was expected as the only reported
Gliclazide Pgp activity found in literature was at very high concentrations. 145
The bulk of the experimental work reported in this paper was performed to evaluate a
large series of sulfonylurea analogs as substrates of the ABC transporters (Pgp and/or
BCRP), and to use this information to build 2D and 3D QSAR models. Based on the
initial experiments, and internal procedures, all the sulfonylurea analogs cell transport
assays were performed at 2µM and measured in triplicate. It is well understood that the
work reported describes local models for both Pgp and BCRP, as all the compounds used
in the study were sulfonylureas, though containing structurally diverse R1 and R2 groups
(described in Appendix I). However, even though structurally similar, the 78 sulfonylurea
analogs spanned approximately 3 logs of Pgp activity and 2 logs of BCRP activity, as
shown in Figures 14 and 15.

Figure 14. Map of all 78 compounds and the respective log Papp activity. Note: red
dotted line represents the activity cutoff value of 0.4 (ER value =2.5).
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Figure 15. Map of all 53 compounds and the respective log BCRP Papp activity. Note: red
dotted line represents the activity cutoff value of 0.4(ER value =2.5.

The compound activity maps in Figures 13 and 14 represent the range of activities for the
molecules used in our research. As you can see, the log normalized range of activity for
all of the compounds was between -0.5 to 2.0. Based on the cutoff values from both of
the transport assays of 2.5 for substrate activity, the cutoff for activity is 0.40 as shown
by the red dotted line in both Figures 13 and 14. The log scale of the activities represents
the activity values from 0 to 56, with negative numbers simply representing the log
calculations of activities less than 1.

MATHEMATICAL MODELS
Molecular dynamics modeling was performed using the VLifeMDS®, version 4.6
software package to evaluate the physico-chemical properties of sulfonylurea molecules
against the biological activity of Pgp efflux. The basic assumption of QSAR and
molecular modeling is that the interactions of the aligned molecules to a probe or model
molecule will provide the necessary features to explain the biological activity. The most
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important assumption then, is that any change in biological activity is directly related to
the changes in the molecular properties. The VlifeMDS® software package has multiple
modeling algorithms available, but only the models used in the present study will be
discussed and explained in more detail here. However, the available modeling algorithms
in the VLifeMDS software package are nearest neighbor (kNN), partial least squares
regression (PLSR), and multiple linear regression (MLR), techniques. An initial
screening of the activity data and each model was performed to determine the best
statistical modeling algorithm to use for our research. For the Pgp work, the kNN and
MLR demonstrated the best model predictions for the 2D and 3D QSAR, respectively.
For the BCRP work, the MLR demonstrated the best model predictions for both the 2D
and 3D QSAR.
Developing QSAR models is an iterative approach, and hundreds of modeling
simulations were performed to evaluate the necessary parameters and build the most
representative models defining each sulfonylurea and ABC transporter activity. The
models presented here represent the most appropriate to define the sulfonylurea-protein
interactions, and the most predictive, and will be discussed individually here.

QSAR DISCUSSION
A QSAR model is a regression or classification model that relates a set of predictor
variables (x) to the potency of a response variable (y). The QSAR model is defined by the
two and three-dimensional descriptors that make up the space surrounding the molecule,
and are important tools to describe the correlation of a biological activity to the molecular
features responsible for the activity. To explain the interaction of the sulfonylureas with
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the Pgp and BCRP proteins, we developed both 2D and 3D QSAR models that will be
described in more depth here.
The 2D QSAR models require calculating molecular descriptors and matching the
molecular descriptors to a biological activity. The 2D modeling and descriptors are the
most widely used, based on their simple nature of employing a direct math algorithm that
is highly reproducible and requires minimal compute time consumption. 146 In contrast,
the 3D QSAR models are more in-depth and require more computational time to
complete the analysis. In the VLifeMDS® software, there are approximately 1300
molecular descriptors used for the 2D QSAR models, whereas the 3D QSAR models use
steric (S) and electrostatic (E) descriptors that specify the region where the structural
feature variation between the test and training set of compounds leads to an increase or
decrease in activity.147 VLifeMDS® comes equipped with numerous statistical modeling
algorithms for both 2D and 3D QSAR modeling, including partial least squares (PLS), knearest neighbor (kNN), and multiple linear regression (MLR). All modeling studies
were performed with the stepwise forward and backward variable selection methods
which resulted in hundreds of models in 2D and 3D space for each protein. The stepwise
forward and backward variable selection is a technique of choosing the predictive
variables that are carried out by the software. The fundamental difference between the
forward and backward selection methods is the use of descriptors (backward) or no
descriptors (forward) to build the model. 148 The Pgp and BCRP models with the greatest
predictive ability were achieved with MLR or kNN regression analysis and will be
described here in more depth.
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The kNN method adopts a nearest neighbor principle for generating the relationship
between the molecular descriptors and a given biological activity. The basic principle of
the kNN classification model is that the compounds are assigned to a class membership
of its nearest neighbors in a common rectangular grid, taking into account the weighted
similarities between a compound and its nearest neighbors. 149, 150 The kNN statistical
methodology is represented by points of the grid in the form of

Y = (point) (value) (point1) (value1)

Equation 4

where: y is the dependent variable (activity), and the points and values represent
descriptors, or steric/electrostatic spaces on the grid.

Also included in the VLifeMDS® software are numerous regression methods to calculate
the best for the data, with the Multiple Linear Regression (MLR) methodology
demonstrated the greatest predictive ability for the sulfonylurea and ABC transporter
protein interactions.151 The MLR methodology relates the dependent variable (activity) to
a number of independent variables (molecular descriptors) through linear equations. The
MLR analysis estimates the values of regression by applying least squares curve fitting
methods. 152, 153 The MLR equation takes the form:

Y = b1* x1 + b2* x2 + b3*x3 + c
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Equation 5

where: Y is the dependent variable (activity), b’s are the regression coefficients of the
corresponding x’s (molecular descriptors), and c is the regression constant (intercept).
Simply stated, the points and values represent molecular descriptors surrounding the
molecule on the grid in 2-dimensional space or the steric and electrostatic descriptors of
the 3-dimensional space.
The predictive ability of the both the 2D and 3D models was evaluated by the crossvalidation (q2) term, employing the leave one out (LOO) methodology. The LOO
principle is a method that computes the statistics for the left-out value, allowing for faster
computation time.154, 155 Simply, in the LOO principle, one data point is selected from the
test set, and the model is built around the remaining points, with the model crossvalidated against the error on the single point held out of the model. This process is then
repeated for each point of the training set and averaging the results in the final model.
The leave one out equation is presented as equation 6 here:

Equation 6

The predictive ability of all the QSAR models was confirmed by the predicted r2
(pred_r2) and the external validation test data set. One final point used in the evaluation
is the standard error of estimation for the cross-validated q2 and the predicted r2, with a
low standard error signifying that the models are statistically significant. In summary, the
VLifeMDS® software program calculates the best model based on the squared
correlation coefficient (r2) which defines the linearity, the cross validated coefficient (q2)
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which is a measure of quality of the fit, and the predicted r2 value. The low standard of
error for each of the terms shows the quality of the fitness of the model, and the Ftest
values demonstrate the variance due to the error of the models, with high F test values
indicating that the models are statistically significant. As there were hundreds of
modeling attempts made, the q2 and pred r2 values were the main factors governing the
selection of the optimal models.
For the modeling work described here, all models were generated using the 70:20:10
approximation; 70% of the molecules were used as the training set, 20% as the test set,
and the remaining 10% as the independent set used for the external validation of the
model. An important note is that the VLifeMDS® program randomly selects the training,
test, and independent set molecules for each model built. For all the sulfonylurea-Pgp
models, this amounted to a training set of 54 compounds, a test set of 15 compounds and
validated with an independent set of 9 compounds. In comparison, all of the sulfonylureaBCRP models used a training set of 38 compounds, a test set of 11 compounds, and 5
compounds used as the independent set to validate the model.
Finally, all the models generated for each protein in both the 2D and 3D space were
evaluated for acceptable performance against linearity, cross-validation, standard error,
and the predictability of the model to identify substrates not in the training or test set.
Many models succeeded in one or two of the criteria, but the models chosen to describe
the behavior had the best balance of high linearity and cross-validation values, low
standard error, and high ability to predict substrate behavior.
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Pgp 2D QSAR DISCUSSION
Of the 200 models run, the optimum model to describe the sulfonylurea-Pgp interaction
within the 2D space was obtained in Model 58, using the kNN methodology with sphere
exclusion. 156 The sphere exclusion technique represents a simple clustering method
whereby molecules are clustered together based on a defined similarity score, continuing
until all molecules are grouped. 157 Model 58 parameters are shown in Table 2 and proved
very robust and an excellent cross validation (q2), with the predicted r2 and externally
validated r2 very close in value, but not over-predicting. This is an important point as
over-predicting models can lead to false predictions, allowing the model to incorrectly
label molecules as substrates/non-substrates for activity. The external predictability of
Model 58 was determined by the predicted r2 (pred_r 2) value, which was 0.8150,
meaning that the model has a prediction rate of 81.5%. This prediction rate is right in
line with the observed Pgp activity data for Glyburide, Glimepiride, Glipizide,
Glisoxepide, and Gliquidone with the model ability to select 4 out of 5 molecules’
activity. Table 1 summarizes the kNN QSAR Model 58.
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Statistical
Parameter
n
k
deg. of free
q2
q2 se
Predicted r2
Predicted r2 se

2D kNN QSAR
Model 58
3
54
46
0.7151
0.2536
0.8150
0.2705

ext val r2
ext val r2 se

0.8288
0.2261

Table 1. Statistical results of 2D QSAR kNN Model 58 for the Sulfonylurea-Pgp activity.

Graphing the predicted vs. the experimental Pgp activity is also a good way to assess
model performance. Model 58 shows good linear correlation between the two data sets,
as presented in Figure 16.

Figure 16. Graphical representation of predicted Pgp activity vs. experimental activity for
the training and test sets for kNN Model 58.
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Table 2. Molecular Descriptors used in 2D QSAR Study
Model Molecular
Descriptor
58

Description

DipoleMoment

DipoleMoment signifies the dipole moment
calculated from the partial charges of the molecule
6chaincount
6chaincount signifies the total number of six
membered rings in a compound
Chi4
Chi4 signifies atomic valence connectivity index
(order 4)
K3alpha
K3alpha signifies the third alpha modified shape
index
SaaaCcount
SaaaCcount signifies the total number of carbons
connected with three aromatic bonds
SAMostHydrophobi SAMostHydrophobicHydrophillicDistance signifies
c
the distance between the most hydrophobic and
hydrophilic point on the vdW surface
HydrophillicDistanc HydrophillicDistance signifies the distance between
e
the hydrophilic groups on the vdW surface
SdssS(sulfate)ESdssS(sulfate)E-index signifies the electropological
index
state indices for the number of sulfate groups
connected with two single and two double bonds

The 2D QSAR model to define the interactions with Pgp had eight 2D contributing
descriptors. The full description of the 2D descriptors of Model 58 are presented in Table
1. The eight descriptors used for Model 58 descriptors are DipoleMoment, 6chaincount,
Chi4, K3alpha, SaaaCcount, SAMostHydrophobic, HydrophillicDistance, and
SdssS(sulfate)E-index. These molecular descriptors characterize the specific information
about the sulfonylureas that drive the interaction with Pgp.
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The 2D equation defining the Pgp and sulfonylurea activity is presented here:

pPgp Efflux = DipoleMoment (5.1080, 5.9350) 6ChainCount (-0.0390, -0.0280) chi4
(2.0000, 3.0000) k3alpha (8.8890, 9.1500) SaaaCcount (6.4530, 8.1170)
SAMostHydrophobicHydrophilicDistance (0.0000, 0.0000) SddssS(sulfate)E-index
(0.0000, 0.0000)
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Molecule

Efflux
Ratio

logEfflux
Ratio

Predicted
logEfflux
Ratio

Residual

Molecule

Efflux
Ratio

logEfflux
Ratio

Predicted
logEfflux
Ratio

Residual

0.246

0.076

0.169

1

6.39

0.806

0.959

-0.153

41

1.76

2

2.75

0.439

0.792

-0.352

42

2.24

0.35

0.397

-0.047

3

6.21

0.793

0.418

0.375

43

1.52

0.182

0.106

0.076

4

5.51

0.741

0.898

-0.157

44

1.09

0.037

0.04

-0.003

5

2.3

0.362

0.458

-0.096

45

1.34

0.127

0.402

-0.275

6

0.93

-0.032

-0.052

0.02

46

1.54

0.188

0.207

-0.019

7

0.9

-0.046

-0.596

0.55

47

3.57

0.553

0.37

0.183

8

0.99

-0.004

0.017

-0.022

48

12.4

1.093

0.695

0.399

9

0.53

-0.276

-0.13

-0.145

49

3.05

0.484

0.685

-0.201

10

0.82

-0.086

-0.056

-0.031

50

5.89

0.77

0.275

0.495

11

0.76

-0.119

-0.13

0.011

51

2.89

0.461

0.627

-0.166

12

0.7

-0.155

0.138

-0.293

52

4.37

0.64

1.001

-0.36

13

0.65

-0.187

-0.132

-0.055

53

12.5

1.097

0.967

0.129

14

0.74

-0.131

-0.114

-0.016

54

9.38

0.972

0.893

0.08

15

0.55

-0.26

-0.121

-0.139

55

1.36

0.134

0.35

-0.217

16

0.56

-0.252

-0.124

-0.128

56

57.4

1.759

1.082

0.677

17

5.4

0.732

0.698

0.034

57

5.35

0.728

0.922

-0.194

18

10.2

1.009

1.027

-0.018

58

7.64

0.883

1.008

-0.125

19

4.17

0.62

0.68

-0.06

59

6.7

0.826

0.861

-0.035

20

2.99

0.476

0.45

0.025

60

16.5

1.217

1.104

0.113

22

9.3

0.968

0.559

0.41

61

3.62

0.559

0.493

0.066

23

2.43

0.386

0.551

-0.165

62

3.08

0.489

0.361

0.128

24

1.33

0.124

0.11

0.013

63

9.74

0.989

0.883

0.106

25

9.73

0.988

0.72

0.268

64

7.81

0.893

0.941

-0.049

26

8.45

0.927

0.976

-0.049

65

14.3

1.155

0.94

0.215

27

3.83

0.583

0.401

0.182

66

11.7

1.068

0.831

0.238

28

12.8

1.107

1.034

0.073

67

1.72

0.236

0.521

-0.285

29

5.41

0.733

0.941

-0.208

68

28.4

1.453

1.315

0.138

30

2.04

0.31

0.636

-0.327

69

25.5

1.407

0.695

0.711

31

8.52

0.93

0.661

0.269

70

7.45

0.872

0.964

-0.092

32

12.9

1.111

1.144

-0.033

71

18.1

1.258

1.393

-0.135

33

21

1.322

1.199

0.123

72

24.3

1.386

1.472

-0.086

34

15.3

1.185

0.899

0.286

73

1.34

0.127

0.428

-0.301

35

3.37

0.528

0.362

0.165

74

1.06

0.025

0.469

-0.443

36

1.56

0.193

0.115

0.078

75

2.93

0.467

0.5

-0.033

37

5.08

0.706

0.878

-0.172

76

4.29

0.632

0.527

0.106

38

0.44

-0.354

0.243

-0.596

77

0.85

-0.072

0.699

-0.771

39

1.62

0.21

-0.064

0.274

78

12.4

1.093

1.098

-0.005

40

0.68

-0.166

0.314

-0.48

79

6.07

0.783

0.797

-0.014

Table 3 Molecules used in study with experimental, predicted, and residual activity.
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To further evaluate the model describing the sulfonylurea and Pgp interaction, the nearest
neighbor algorithm was performed at three, six, or nine nearest neighbors for the
calculations. Though all the models presented similar results, the kNN models with the
increased nearest neighbor values did not outperform the simpler Model 58 with only
three nearest neighbor parameters. In fact, as shown in Table 4, Model 58 with the n = 3
parameter outperformed the n = 6 and n= 9 nearest neighbor models with better Predicted
r2 and Ext Val r2 values, in a head to head comparison. The three most representative
kNN models using the 3, 6, and 9 nearest neighbors are presented in Table 4 for
comparison.

Statistical
Parameter
n
k
deg. of free
q2
q2 se
Predicted r2
Predicted r2
se
ext val r2
ext val r2 se

2D kNN
QSAR Model
58
3
54
46
0.7151
0.2536
0.8150
0.2705

2D kNN
QSAR Model
31
6
54
48
0.7306
0.2606
0.7961
0.2120

2D kNN QSAR
Model 50

0.8288
0.2261

0.7706
0.2727

0.7880
0.2472

9
54
48
0.7210
0.2626
0.6312
0.3149

Table 4. Comparison of the 3-6-9 nearest neighbors Models for Pgp

This was relatively unexpected as usually the more neighbors, the more rigorous the
calculations due to the larger fields of interaction, and hence a better model. However,
the structural similarity of the sulfonylurea analogs made the selection of a larger nearest
neighbor factor an insignificant point. As the longer and more extensive calculations for
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increased nearest neighbor parameters did not prove to be a better modeling assumption,
further modeling attempts will be performed as simple as possible, increasing the
throughput without sacrificing robustness. As you presented in Table 4 above, the nearest
neighbor calculations for the n = 3, 6, or 9 values were close but turned out to be not that
as predictive as the Model 58 (n = 3). Comparing the models, we see that the cross
validation was better in the n = 6 and 9 models (0.7151 to 0.7306 to 0.7210); however,
the n = 3 model beat the others in both the pred_r2 (0.8150 compared to 0.7961 and
0.6312), and external validation r2 (0.8288 compared to 0.7706 and 0.7880).

BCRP 2D QSAR DISCUSSION
The optimum model to describe the sulfonylurea-BCRP interaction within the 2D space
was obtained in Model 89, using the MLR methodology, with the sphere exclusion
technique. 158 Model 89 parameters are shown in Table 3, proved very robust and an
excellent cross validation (q2), with the predicted r2 and externally validated r2 also very
close to in value, but not over-predicting, similar to the model for Pgp. The external
predictability of Model 89 was determined by the predicted r2 (pred_r 2) value, which
was 0.7711, meaning that the model has a prediction rate of 77.11%.
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Statistical
Parameter
n
deg. of freedom
r2
q2
Ftest
r2 se
q2 se
Predicted r2
Predicted r2 se
External val r2
Ext val r2 se

2D QSAR MLR
Model 89
38
30
0.8690
0.8131
28.4199
0.1548
0.1849
0.7711
0.1856
0.9185
0.1397

Table 5. Statistical results of BCRP 2D QSAR MLR model

As shown in Table 5 above, the MLR Model 89 also proved very robust and
demonstrated excellent linearity with low standard error. Model 89 models was very
accurate, with excellent cross validation (q2), with the predicted r2 and externally
validated r2 very close in value, but as seen in the Pgp model, also not over-predicting.
The external predictability of Model 89 was determined by the predicted r2 (pred_r 2)
value, which was 0.9185, meaning that Model 89 has an external prediction rate of
91.85%.
Graphing the predicted verse the experimental Pgp activity also demonstrated the linear
correlation between the two and is presented in Figure 17.
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Figure 17. Predicted BCRP activity vs. experimental activity for the training and test sets
for model 89.

There were seven 2D contributing descriptors for Model 89. The seven descriptors used
in Model 89 are the vdWSurfaceArea, SKMostHydrophobicHydrophilicDistance,
SAMostHydrophobicHydrophilicDistance, YcompDipole, SddssS(sulfate)E-index,
DipoleMoment, and SsNH2E-index. These molecular descriptors characterize the
specific information about the sulfonylureas that drive the interaction with BCRP. The
full description of the 2D descriptors of Model 89 are presented in Table 6.
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Table 6. Molecular Descriptors used in BCRP 2D QSAR Study
Model Molecular
Descriptor
89

Description

vdWSurfaceArea

This descriptor signifies total van der Waals surface
area of the molecule
SKMostHydrophobi SKMostHydrophobicHydrophilicDistance signifies
cHydrophilicDistan the most hydrophobic value on the van der Waals
ce
surface (by Kellog Method using Slogp)
SAMostHydrophobi SAMostHydrophobicHydrophillicDistance signifies
cHydrophilicDistan the distance between the most hydrophobic and
ce
hydrophilic point on the vdW surface
YcompDipole
YcompDipole signifies the y component of the dipole
moment (external coordinates)
SddssS(sulfate)ESdssS(sulfate)E-index signifies the electropological
index
state indices for the number of sulfate groups
connected with two single and two double bonds
DipoleMoment
DipoleMoment signifies the dipole moment
calculated from the partial charges of the molecule
SsNH2E-index
SsNH2E-index signifies the electropological state
indices for the number of -NH2 groups connected
with two single bonds

Another way to assess the 2D molecular descriptors in Model 89 is to understand the
weight % contributions of each descriptor. As shown in Figure 18, four of the molecular
descriptors had positive contributions on the model: vdWSurfaceArea,
SAMostHydrophobicHydrophilicDistance, YcompDipole, and SsNH2E-index
contributing approximately 70% to the model overall. Three molecular descriptors had
negative contributions on the model: SKMostHydrophobicHydrophilicDistance,
SddssS(sulfate)E-index, and DipoleMoment contributing the remaining 30% to the
model. The % contribution values of each molecular descriptor are presented in Figure
18.
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Figure 18. Graph depicting 2D QSAR variables and % contributions.

The 2D equation defining the BCRP and sulfonylurea activity is presented here:
pBCRPEfflux = vdWSurfaceArea 0.0038(±0.0003)
SKMostHydrophobicHydrophilicDistance -0.0315(±0.0072)
SAMostHydrophobicHydrophilicDistance 0.0316(±0.0089) YcompDipole
0.0531(±0.0134) SddssS(sulfate)E-index -0.0600(±0.0175) DipoleMoment 0.0562(±0.0237) SsNH2E-index 0.0445(±0.0207) -1.6761
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Efflux
Ratio

logEfflux
Ratio

Predicted
logEfflux
Ratio

Residual

Efflux
Ratio

logEfflux
Ratio

Predicted
logEfflux
Ratio

Residual

1

2.78

0.444

0.519

-0.075

29

3.34

0.524

0.681

-0.157

2

1.9

0.279

0.225

0.054

30

1.49

0.173

0.473

-0.299

3

3.21

0.507

0.32

0.187

31

3.37

0.528

0.337

0.191

4

3.45

0.538

0.437

0.101

32

4.28

0.631

0.404

0.227

5

1.14

0.057

0.081

-0.024

32

4.28

0.631

0.404

0.227

6

1.01

0.004

-0.138

0.143

33

3.32

0.521

0.528

-0.007

7

0.88

-0.056

-0.343

0.288

34

7.67

0.885

0.765

0.119

8

0.87

-0.06

0.057

-0.118

35

3.9

0.591

0.497

0.094

9

0.67

-0.174

-0.219

0.045

36

1.87

0.272

0.242

0.03

10

0.54

-0.268

-0.133

-0.134

37

2.75

0.439

0.539

-0.1

11

0.55

-0.26

-0.254

-0.006

38

0.877

-0.057

0.231

-0.288

12

0.59

-0.229

-0.148

-0.081

39

1.76

0.246

0.223

0.023

13

0.72

-0.143

-0.273

0.13

40

0.881

-0.055

0.306

-0.361

14

0.91

-0.041

-0.018

-0.023

41

13.1

1.117

1.06

0.057

15

0.44

-0.357

-0.371

0.014

42

3.7

0.568

0.686

-0.118

16

0.5

-0.301

-0.474

0.173

43

8.33

0.921

0.829

0.091

17

2.32

0.365

0.545

-0.179

44

1.3

0.114

0.284

-0.17

Molecule

Molecule

8

3.72

0.571

0.721

-0.151

45

13.4

1.127

1.237

-0.11

19

2.41

0.382

0.358

0.024

46

6

0.778

0.747

0.031

20

1.76

0.246

0.277

-0.031

47

4.54

0.657

0.679

-0.022

22

2.4

0.38

0.194

0.186

48

7.45

0.872

0.808

0.064

23

6.54

0.816

0.583

0.233

49

12.4

1.093

1.102

-0.008

24

1.65

0.217

0.14

0.077

50

2.3

0.362

0.561

-0.199

25

4.18

0.621

0.497

0.124

51

3.13

0.496

0.474

0.022

26

3.67

0.565

0.455

0.11

52

0.73

-0.137

0.114

-0.25

27

2.72

0.435

0.575

-0.14

53

4.11

0.614

0.664

-0.05

28

5.43

0.735

0.548

0.187

54

3.88

0.589

0.599

-0.01

Table 7. Molecules used in the BCRP study with experimental, predicted and residual
activity values.

The sulfonylurea interactions with Pgp and BCRP were well characterized in the
respective 2D QSAR models. Both 2D QSAR models were comprised 7 and 8 molecular
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descriptors defining the activity in BCRP and Pgp, respectively. Most of the descriptors
defining the activity for either Pgp of BCRP were unique, however there were 3
descriptors that were shared in the 2D models. The max hydrophibic-hydrophillic
distance (positive coefficient for both), the sulfate index (negative coefficient for BCRP,
positive for Pgp) and the dipole moment (negative coefficient for BCRP and positive for
Pgp) were shared in both models and are therefore important features to describe the
sulfonylurea interactions with the ABC transporter proteins in general. Examining the
values individual values for each descriptor demonstrate the impact on each model and
help us understand the importance of each on the respective models. It is difficult to
compare the importance of the descriptors in each model directly due to the nature of the
statistical analysis (kNN vs MLR), however the similarity in the structure and function of
the molecules cannot be overlooked when dealing with the ABC transporters. The shared
descriptors and the definitions are presented in Table 8.

Table 8. Descriptors shared by both Pgp and BCRP 2D QSAR Models
Molecular
Descriptor
SAMostHydrophobi
cHydrophilicDistan
ce
SddssS(sulfate)Eindex
DipoleMoment

Description
SAMostHydrophobicHydrophillicDistance signifies the
distance between the most hydrophobic and hydrophilic
point on the vdW surface
SdssS(sulfate)E-index signifies the electropological state
indices for the number of sulfate groups connected with two
single and two double bonds
DipoleMoment signifies the dipole moment calculated from
the partial charges of the molecule
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Pgp 3D QSAR DISCUSSION
The optimum model to describe the sulfonylurea-Pgp interaction with the 3D space was
obtained in Model 10, using the MLR methodology, also using the sphere exclusion
technique, and with the added Del Re energy minimization calculations for the 3dimensional space. 159 Del Re energy minimizations are based on the dissociation
energies of the bonds, accounting for the overlap of the dipole moments and often used in
QSAR modeling parameterization. 160 Model 10 parameters are presented in Table 4 and
proved very robust and demonstrated excellent linearity with an r2 value of 0.8304, a
cross validation value of 0.7501, and a predicted r2 value of 0.7349, also not
overpredicting against the external validation r2 of 0.8806. The external predictability of
Model 11 was determined by the predicted r2 (pred_r 2) value, which was 0.8806,
meaning that the model has a prediction rate of 88.06%. The 3D model was better than
the 2D QSAR model in the cross validation (q2 of 0.7501 vs 0.7151) and external
validation r2 (0.8806 vs 0.8266); however, the predicted r2 capability was better in the 2D
model (0.8150 vs 0.7349).

The 3D QSAR model statistical parameters and values are presented in table 9.
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Table 9. The Pgp 3D QSAR Model Statistical Parameters and Values.

Statistical
Parameter

3D QSAR MLR
Model 10

n
deg. of freedom
r2
q2
Ftest
r2 se
q2 se
Predicted r2
Predicted r2 se
External val r2
Ext val r2 se

58
44
0.8304
0.7501
19.5892
0.2128
0.2584
0.7349
0.6234
0.8806
0.1683

Plotting the predicted Pgp activity against the experimental activity also provides an
assessment of the model. As shown in Figure 19, the predicted vs experimental Pgp
activity for the training and test sets showed excellent linearity. There was one outlier in
the test set (molecule 77) that had a very high Papp value (12.4) but was predicted to be
low due to the 2-methyltetrahydrofuran ligand attached to the benzamido group.
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Figure 19. Graphical representation of predicted Pgp activity vs. actual activity for the
training and test sets for MLR Model 10.

There were eleven 3D descriptors for Model 10 representing the steric and electrostatic
space contributing to the activity model, as presented in Figure 19. The descriptors are
denoted as electrostatic (E) or steric (S), and the corresponding number is the location of
the grid surrounding the molecule. The steric descriptors represented the largest positive
contributors to the QSAR model with S_1446, S_1970, S_3790, S_2316, S_1715, S_834,
S_2320, and S_3219 positively contributing to the model, and accounting for
approximately 75% of the weighted activity overall. One steric descriptor (S_1060) and
the two remaining electrostatic descriptors (E_3205 and E_714) negatively contributed to
the interaction.
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Figure 20. Steric and Electrostatic descriptors contributions for the 3D QSAR modeling
of Pgp activity for 3D QSAR del re energy minimization.

Figure 21. Glyburide molecule showing the points of Pgp 3D model.

The plots in Figure 21, show the steric and electrostatic field points indicating the region
of local fields round the aligned molecule Glyburide. The colored spheres (blue and
green) represent the fields, steric and electrostatic, respectively. In the 3D QAR model,
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the steric descriptors with positive values represent areas with high steric tolerances,
meaning bulky groups would be favored; and steric descriptors with negative values
indicate areas with low tolerance, meaning smaller groups would be favored. The
electrostatic descriptors with positive values represent areas where electron-donating
groups are favored; and the negative values represent areas where the electronwithdrawing groups are favored.

The equation governing the sulfonylurea-Pgp 3D QSAR model is:
pPgp Effluxgas mars = - 0.0152(±0.0024) (S_1060) + 0.0236(±0.0030) (S_1446) +
0.0163(±0.0026) (S_1970) + 0.0134(±0.0058) (S_3790) + 0.0167(±0.0032) (S_2316) +
0.0170(±0.0036) (S_1715) + 0.0149(±0.0032) (S_834) + 0.0085(±0.0028) (S_2320) +
0.0177(±0.0039) (S_3219) -0.0357(±0.0126) (E_3205) -0.0493(±0.0176) (E_714) +
0.2696

The equation above shows the contributions for the various descriptors contributing to the
explanation of the Pgp activity. Those descriptors having a positive value shows that an
increase is needed for Pgp activity. Conversely, there were three descriptors that show an
inversely proportional relationship in that decreasing the value of that descriptor will
increase the Pgp activity. From the model it is observed that the electrostatic fields E_714
and E_3205 have negative coefficients on both the cyclohexyl moiety and on the
carbonyl of the amide, respectively. Also, the negative coefficient on steric descriptor
S_1060 shows that the cyclohexyl ring needs smaller group at that position to increase
the Pgp activity. The remaining steric field descriptors have positive coefficients, and
therefore would require bulkier groups to increase the Pgp activity. The S_1446, S_1715,
S_1970, S_2316, S_2320, S_3129, and S_3790 steric descriptors show an increase in Pgp
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activity with the increased bulky groups at the cyclohexyl ring, urea, sulfonyl, central aryl
ring, benzamido, and the halogen substitution of the benzamido group, respectively.

Pred

Efflux
Ratio

logER
Ratio

1

6.39

0.806

0.635

0.17

2

2.75

0.439

0.246

0.194

3

6.21

0.793

0.384

4

5.51

0.741

5

2.3

0.362

6

0.93

7

0.9

8

0.99

9

0.53

10

Pred

Efflux
Ratio

logER
Ratio

41

1.76

0.246

0.226

42

2.24

0.35

0.197

0.153

0.409

43

1.52

0.182

0.209

-0.027

0.557

0.184

44

1.09

0.037

-0.012

0.05

0.394

-0.033

45

1.34

0.127

0.125

0.002

-0.032

0.16

-0.191

46

1.54

0.188

0.146

0.041

-0.046

0.151

-0.197

47

3.57

0.553

0.661

-0.108

-0.004

0.288

-0.292

48

12.4

1.093

1.31

-0.217

-0.276

-0.141

-0.135

49

3.05

0.484

0.922

-0.438

0.82

-0.086

0.354

-0.441

50

5.89

0.77

0.177

0.593

11

0.76

-0.119

-0.236

0.117

51

2.89

0.461

0.286

0.175

12

0.7

-0.155

0.38

-0.535

52

4.37

0.64

0.754

-0.113

13

0.65

-0.187

0.267

-0.454

53

12.5

1.097

0.99

0.107

14

0.74

-0.131

0.175

-0.306

54

9.38

0.972

1.16

-0.188

15

0.55

-0.26

-0.264

0.004

55

1.36

0.134

0.015

0.118

16

0.56

-0.252

-0.277

0.025

56

57.4

1.759

0.616

1.143

17

5.4

0.732

0.717

0.016

57

5.35

0.728

0.187

0.541

18

10.2

1.009

0.924

0.085

58

7.64

0.883

0.851

0.032

19

4.17

0.62

0.746

-0.126

59

6.7

0.826

0.687

0.139

20

2.99

0.476

0.122

0.354

60

16.5

1.217

1.433

-0.216

22

9.3

0.968

0.793

0.176

61

3.62

0.559

0.735

-0.176

23

2.43

0.386

0.467

-0.081

62

3.08

0.489

0.466

0.022

24

1.33

0.124

0.068

0.056

63

9.74

0.989

1.062

-0.073

25

9.73

0.988

0.606

0.382

64

7.81

0.893

0.753

0.139

26

8.45

0.927

0.727

0.2

65

14.3

1.155

1.162

-0.007

27

3.83

0.583

0.452

0.132

66

11.7

1.068

0.934

0.134

28

12.8

1.107

1.107

0

67

1.72

0.236

0.24

-0.004

29

5.41

0.733

0.632

0.101

68

28.4

1.453

1.309

0.145

30

2.04

0.31

0.259

0.05

69

25.5

1.407

1.477

-0.07

31

8.52

0.93

0.02

0.91

70

7.45

0.872

0.991

-0.119

32

12.9

1.111

1.034

0.077

71

18.1

1.258

0.828

0.43

33

21

1.322

0.633

0.69

72

24.3

1.386

1.375

0.01

34

15.3

1.185

1.271

-0.086

73

1.34

0.127

0.077

0.051

35

3.37

0.528

0.562

-0.035

74

1.06

0.025

-0.104

0.13

36

1.56

0.193

0.096

0.097

75

2.93

0.467

0.574

-0.107

37

5.08

0.706

0.825

-0.119

76

4.29

0.632

0.517

0.115

38

0.44

-0.354

0.147

-0.5

77

0.85

-0.072

0.945

-1.017

39

1.62

0.21

0.122

0.088

78

12.4

1.093

0.908

0.185

40

0.68

-0.166

0.224

-0.39

79

6.07

0.783

0.661

0.123

Molecule

Residual

Molecule

logER

58

Residual
logER
0.019

Table 10. Molecules used in the Pgp study with experimental, predicted and residual
activity values.

BCRP 3D QSAR DISCUSSION
The optimum model to describe the sulfonylurea-BCRP interaction with the 3D space
was obtained in Model 65, using the MLR methodology, also using the sphere exclusion
technique, and with Gasteiger Marsili energy minimization calculations.

161

Gasteiger

Marsili energy calculation for the 3D space is a method of calculating the energies of the
atomic charges in the sigma and pi systems and is also used routinely as an energy
calculation tool for QSAR modeling.162 Model 65 also proved very robust and
demonstrated excellent linearity with an r2 value of 0.9063%, a cross validation value of
0.7789 and a predicted r2 value of 0.8687. The predictive ability of all the 3D QSAR
models was further confirmed by the predicted r2 and the external validation test data set,
both of which demonstrated excellent acceptance criteria with only a slight
overprediction when comparing the predicted r2 to the external validation r2 values.
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The BCRP 3D QSAR model statistical parameters and values are presented in table 11.
Statistical
Parameter
n
deg. of freedom
r2
q2
Ftest
r2 se
q2 se
Predicted r2
Predicted r2 se
External val r2
Ext val r2 se

3D QSAR MLR
Model 65
58
32
0.9063
0.7789
38.7034
0.1290
0.1981
0.8687
0.2092
0.8121
0.3436

Plotting the predicted BCRP activity against the actual experimental activity also
provides an assessment of the model. As shown in Figure 22 the predicted vs actual
BCRP activity for the training and test sets showed excellent linearity.

Figure 22. Graphical representation of predicted BCRP activity vs. actual activity for the
training and test sets for MLR Model 65.

There were eight 3D contributing descriptors for Model 65 representing the steric and
electrostatic space surrounding the molecules. For reference, the descriptors are denoted
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as electrostatic (E) or steric (S), and the corresponding number is the location of the grid
surrounding the molecules. The steric descriptors were the largest positive contributors
to the QSAR model with the S_1940, S_1950, and S_1292 descriptors contributing
approximately 58% to the overall model. The steric descriptor S_1926 and S_2156, and
the electrostatic descriptors E_1375, E_1458, and E_2086 contributed negatively to the
interactions. contribution plot in Figure 23 accounts for the individual descriptors
contributions toward the biological activity.

Figure 23. Steric and Electrostatic descriptors contribution plots for the 3D QSAR
modeling of BCRP activity for 3D QSAR Model 65 Gasteiger-Marsili energy
minimization.

The equation governing the 3D QSAR model is:
pBCRP Efflux = 0.0205(±0.0015) (S_1940) + 0.0164(±0.0018) (S_1950) +
0.0209(±0.0023) (S_1292) - 0.0652(±0.0107) (E_1375) - 0.0134(±0.0027) (S_1926) 0.0203(±0.0048) (S_2156) + 0.0149(±0.0032) (S_834) - 0.0134(±0.0027) (S_2156) 0.0203(±0.0048) (E_1458) -0.0225(±0.0041) (E_1458) -0.0370(±0.0099) (E_2086) –
0.0011
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The equation above shows the contributions for the various descriptors contributing to the
explanation of the BCRP activity. Those descriptors having a positive value shows that
an increase in that descriptor increases the BCRP activity. Conversely, there were three
descriptors that shown an inversely proportional relationship in that decreasing the value
of that descriptor will increase the BCRP activity. From the model it is observed that the
electrostatic fields E_714 and E_3205 need more negative ligands to increase activity,
with a negative coefficient on both the cyclohexyl moiety and on the carbonyl of the
amide, respectively. Also, the steric descriptor S_1060 shows that the cyclohexyl ring
needs smaller group at that position. The field points model is shown in Figure 24.

Figure 24. Field point model detailing steric and electrostatic descriptors for the 3D
QSAR Modeling.

The plot of steric and electrostatic field points indicates the region of local fields around
the aligned molecules. 163 The colored spheres (blue and green) represent the fields, steric
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and electrostatic, respectively. In the 3D QAR model, the steric descriptors with positive
values represent areas with high steric tolerances, meaning bulky groups would be
favored; and steric descriptors with negative values indicate areas with low tolerances,
meaning smaller groups would be favored. The electrostatic descriptors with positive
values represent areas where electron-donating groups are favored; and the negative
values represent areas where the electron-withdrawing groups are favored.
From the model it is observed that the steric fields S_1940, S_1950, and S_1292 have
positive coefficients, meaning that an increase in bulky groups on the benzamido and
sulfonylurea ligands, respectively, will increase the BCRP activity. Similarly, the steric
and electrostatic descriptors with negative coefficients require smaller or more negative
ligands to increase activity. The steric descriptors S_1926 and S_2156 negative
coefficients mean that smaller ligands at the far side of the substituted benzyl ring will
increase activity. The electrostatic descriptors E_1375, E_2086 and E_1458 have
negative coefficients that dictate more negative ligands need to be present on the
benzamido and central ring to increase activity.
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Efflux
Ratio

logEfflux
Ratio

Predicted
logEfflux
Ratio

Residual

1

2.78

0.444

0.201

0.243

2

1.9

0.279

0.2

0.079

3

3.21

0.507

0.734

4

3.45

0.538

0.385

5

1.14

0.057

6

1.01

0.004

7

0.88

8

Molecule

Efflux
Ratio

logEfflux
Ratio

Predicted
logEfflux
Ratio

Residual

29

3.34

0.524

0.596

-0.073

30

1.49

0.173

0.623

-0.45

-0.228

31

3.37

0.528

0.653

-0.126

0.153

32

4.28

0.631

0.573

0.058

0.057

0

32

4.28

0.631

0.831

-0.199

0.212

-0.207

33

3.32

0.521

0.669

-0.148

-0.056

0.106

-0.161

34

7.67

0.885

0.766

0.119

0.87

-0.06

-0.025

-0.035

35

3.9

0.591

0.573

0.018

Molecule

9

0.67

-0.174

-0.19

0.016

36

1.87

0.272

-0.037

0.309

10

0.54

-0.268

0.008

-0.276

37

2.75

0.439

0.493

-0.054

11

0.55

-0.26

-0.268

0.008

38

0.877

-0.057

0.055

-0.112

12

0.59

-0.229

0.05

-0.279

39

1.76

0.246

0.239

0.007

13

0.72

-0.143

-0.263

0.12

40

0.881

-0.055

0.073

-0.128

14

0.91

-0.041

-0.275

0.235

41

13.1

1.117

0.84

0.277

15

0.44

-0.357

-0.049

-0.308

42

3.7

0.568

0.38

0.189

16

0.5

-0.301

-0.171

-0.13

43

8.33

0.921

0.766

0.154

17

2.32

0.365

0.505

-0.14

44

1.3

0.114

0.05

0.064

18

3.72

0.571

0.624

-0.054

45

13.4

1.127

1.179

-0.052

19

2.41

0.382

0.258

0.124

46

6

0.778

0.621

0.157

20

1.76

0.246

0.661

-0.415

47

4.54

0.657

0.747

-0.089

22

2.4

0.38

0.73

-0.35

48

7.45

0.872

0.631

0.241

23

6.54

0.816

1.083

-0.267

49

12.4

1.093

1.178

-0.085

24

1.65

0.217

0.444

-0.227

50

2.3

0.362

0.583

-0.222

25

4.18

0.621

0.654

-0.032

51

3.13

0.496

0.628

-0.132

26

3.67

0.565

0.631

-0.067

52

0.73

-0.137

-0.234

0.098

27

2.72

0.435

0.37

0.065

53

4.11

0.614

0.614

0

28

5.43

0.735

0.665

0.069

54

3.88

0.589

0.55

0.039

Table 12. Molecules used in the BCRP study with experimental, predicted and residual
activity values.

PHARMACOPHORE MODELING DISCUSSION
A pharmacophore model is a 3D representation of the steric and electrostatic features
needed to ensure the optimal molecular interactions with the desired biological activity.
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Pharmacophore identification studies were performed using the MolSign module of

the VLifeMDS® v4.6 software package. In general, the pharmacophore models consist of
Hydrogen bond donors, Hydrogen bond acceptors, aromatic/hydrophobic groups, and
positive of negative ionizable groups. The features of the pharmacophore are color coded
as Hydrogen bond donors (Green), Hydrogen bond acceptors (Blue), hydrophobic
(Orange), Aliphatic (Buff), Negative (Dark Red), and Positive (Dark Green). For visual
reference, the software designates the smaller colored spheres to represent the key
features of Glyburide, with the larger spheres representing the more common key features
across the series of sulfonylurea analogs (larger spheres are shown in Pharmacophore
models). In the case of Glyburide, there were 12 key pharmacophore points identified in
the molecule, as shown in Figure 25.

Figure 25. Glyburide Pharmacophore features.

Like the QSAR modeling efforts, the first and second-generation sulfonylureas were
analyzed against the low energy conformer Glyburide as the template. As expected, only
5 of the sulfonylureas overlaid precisely to the core conformer structure. The first65

generation sulfonylureas are lacking the benzamido ligand of the scaffold and therefore
only partially fit the conformer; with Glimepiride, Glisoxepide, Gliquidone, Glipizide,
and Gliclazide, all fit the scaffold overlay.
For the pharmacophore evaluation, the 45 sulfonylurea analogs demonstrating Pgp
activity, and the 25 sulfonylureas demonstrating BCRP activity were used to build the
respective models. In the VLifeMDS® MolSign software module, Glyburide was loaded
as the reference molecule. There are three parameters to optimize that influence the
pharmacophore generation: primary feature count, tolerance limit and maximum distance
allowed. Briefly, the primary feature count is the number of features in the
pharmacophore; the tolerance limit is set to between 10-30% and accounts for variability
in the pharmacophore features; and the max distance allowed determines how far apart a
feature can be from another (max distance is 15Å). For the pharmacophore generation,
the parameters where optimized to capture the best feature coverage of the molecules in
the study. For both the reported Glyburide pharmacophores, the feature count was set to
5, the tolerance limit was set to 10%, and the max distance was set to 10Å.
These parameters were optimized to maximize the pharmacophore model activity to
capture as many molecular features as possible without dampening the sensitivity. Too
few or too many features will not allow for a robust model by including too many or too
few molecules in the model. Meaning, allowing for too wide criteria on the tolerance may
include features that are not shared across the entire molecule set; on the feature count,
limiting the feature count to a reasonable value (i.e., 5) forces the algorithm to pick the
best features to define the activity without selecting the entire molecule; and limiting the
distance allows for feature resolution across the entire molecule. The impact of these
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assumptions is that we are building a local model maximizing the activity of the
sulfonylureas against Glyburide, to best explain the transport behavior of Glyburide in
the ABC transporters Pgp and BCRP.
From the pharmacophore generation, the sulfonylurea-Pgp and sulfonylurea-BCRP
pharmacophores each contained 5 key features describing the steric and electrostatics of
the protein-sulfonylurea activity. The key pharmacophore features were aromatic rings,
hydrogen donors, and hydrogen acceptors. Though these features were similar across
both ABC transporter models, there were important differences concerning the activities
and therefore the pharmacophore models will be discussed separately.

SULFONYLUREA-Pgp PHARMACOPHORE
The sulfonylurea-Pgp pharmacophore contained 5 features, 2 aromatic rings, 1 Hydrogen
donor, and 2 Hydrogen acceptors, as pictured in Figure 26. The H donor feature was
assigned to the amide of the sulfonylurea, with the H acceptors being the carbonyl of the
sulfonylurea and benzamido moieties. The benzamido and aryl ring accounted for the two
aromatic rings. The 5-point pharmacophore was supported by 39 of the 45 molecules,
sharing all five of the key features. This was the maximum number of sulfonylurea
analogs included with the 5-feature pharmacophore. The inclusion rate was higher with
less features of the pharmacophore, but the pharmacophore was not as strong at
explaining the features responsible for the activity. This is an important step in
pharmacophore generation, the pharmacophore model should represent the activity of the
molecules studied as closely as possible.
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Figure 26. Glyburide Pharmacophore detailing the 5 points of interest.
As expected, the 5 second generation sulfonylureas fit the pharmacophore template well,
being similar in size and structure to Glyburide. The first-generation sulfonylureas
however are much smaller in size and do not contain the ligands attached at the para
position of the arylsulfonylurea core structure. For reference, the core sulfonylurea
structure is presented in Figure 26, with the para position of the arylsulfonylurea ring
denoted as R1 circled in blue.

Figure 26. Sulfonylurea-BCRP Pharmacophore denoting the para position of the
arylsulfonylurea ring.
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SUFONYLUREA-BCRP PHARMACOPHORE
Similar to the Pgp pharmacophore, the sulfonylurea-BCRP pharmacophore contained 5
features, but differed in the types and location of the features. The 2 aromatic rings, 1
Hydrogen donor, 1 Hydrogen acceptors, and 1 hydrophobic as pictured in Figure 27. The
H donor feature was assigned to the amide of the sulfonylurea, with the H acceptor
assigned to the carbonyl of the benzamido moiety. As expected, the benzamido and aryl
rings accounted for the two aromatic rings. The hydrophobic feature was assigned to the
substituted benzamido ring, near the Chlorine. The 5-point BCRP pharmacophore was
supported by 21 of the 25, sharing all five of the key features to represent the broadest
group of the molecule set. Again, this was the highest number of sulfonylureas included
in the 5-point pharmacophore. The inclusion rate was higher for lower feature count
pharmacophores but did not represent all of the key features properly. The
pharmacophore model is presented in Figure 28.

Figure 28. Glyburide-BCRP Pharmacophore detailing the 5 points of interest.
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PHARMACOPHORE MODELING DISCUSSION
The value of the pharmacophore model is the highlight of the ligands at certain points on
the molecule structure that drive the structure activity relationship. This is possible to
accomplish as all of the molecules in the study have been normalized to the most active
molecule (Glyburide), providing the means to identify the structural changes that are
believed to be implicated in the observed pharmacological activity.
The two pharmacophore models generated showed many similarities and some
interesting differences. Both models shared the two aromatic rings, but differed in the
hydrogen donor, hydrogen acceptor and hydrophobic features. For the Pgp
pharmacophore, the H donor feature represented the amide of the sulfonylurea, with the
H acceptors being the carbonyls of the sulfonylurea and benzamido moieties. The Pgp
pharmacophore represented a uniform feature distribution across the molecule driving the
activity. The BCRP pharmacophore however, highlighted the importance of the
substituted benzamido ligand for BCRP activity, with the H donor feature representing
the amide of the sulfonylurea, the H acceptor representing the carbonyl of the benzamido
moiety, and the hydrophobic feature was assigned to the substituted benzamido ring, near
the Chlorine. This hydrophobic character is the main difference between the Pgp and
BCRP activity models.
This combination of hydrophilic and hydrophobic character matches well with the
understanding that these ABC proteins rely on these broad moieties instead of very
specific chemical structures. 165 Clearly from both models, the activity in both the Pgp
and BCRP models was driven by the arylsulfonylurea and the substituted benzamido
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ring. The non-substrates of both proteins were lacking at least the benzamido ligand and
the steric and electrostatic character that it brings.
As expected, a large set of the sulfonylurea analogs that do not have Pgp or BCRP
activity, also contain some or all of these features. However, for those molecules that do
not have all the key feature points for either pharmacophore, the activity is obviously
lacking. For those molecules that share the key features, but still lack activity, there were
a few noticeable differences. These molecules also had other substituents that interfered
with the activity, bulky groups, or electron withdrawing/adding.
As there is no crystal structure of Pgp or BCRP currently available, the pharmacophore
model allows for a mapping of the key features on the molecule that relate to an increase
in activity. The specificity of the pharmacophore model will be lacking as a true binding
pocket definition of size and electrostatics for either protein is not known. However, the
pharmacophore models for both Pgp and BCRP represent the key molecular features
(steric/electrostatic character) of the ligands on the molecule Glyburide that explain the
ABC transporter activity.

GENERAL DISCUSSION
The oral hypoglycemic sulfonylurea molecule Glyburide has been shown to be actively
transported from various biological tissues though a pronounced interaction with the ATP
binding cassette (ABC) active transporter proteins. In our research, the interactions of a
series of sulfonylureas and two of the ABC transporter proteins (Pgp and BCRP) were
studied in two MDCK cell monolayer transport assays, MDCK-MDR and MDCK-BCRP.
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The cell lines are rigorously characterized and shown to have no other transporter
proteins present, so the transport activity is regarded as a direct effect of the molecule and
the specific protein.
In total, 78 sulfonylurea analogs were used in the Pgp assays, and 54 were used in the
BCRP assay. A subset of these sulfonylurea analogs exhibited either Pgp or BCRP
activity with 45 demonstrating Pgp substrate activity, and 25 demonstrating BCRP
activity. Substrate activity was determined based on the Efflux Ratios (ER), which is the
ratio of the transport in the basolateral to apical direction divided by the transport in the
apical to basolateral direction. The integrity of the cell monolayers was check by transepithelial resistance measurements, and the ER benchmarked with positive and negative
controls, showing the cell monolayers are performing as expected. The negative control
for both assays was antipyrine, which demonstrated equivalent transport in both
directions; and compounds were chosen for the positive controls that are known
substrates for each protein. Specifically, the positive controls were topotecan for the
MDCK-BCRP cells, and vinblastine for the MDCK-MDR cells. The molecules whose
ER in the Pgp an BCRP transport assays were ≥ 2.5 (2.5 times greater transport in one
direction) were considered substrates. The second-generation sulfonylureas and analogs
demonstrated considerable Pgp and BCRP activity, further confirming the ability of the
sulfonylurea analogs to be substrates of both ABC transporter proteins.
Care was taken to select the experimental concentrations that resulted in relevant and
comparable results between the two studies. Of special note are the three sulfonylureas
Glimepiride, Glisoxepide and Gliquidone, that were identified as substrates of Pgp and

72

BCRP and have not been previously reported. Our results also confirm Glyburide as a
substrate of Pgp and BCRP, as previously reported. 166
The first reported carrier mediated transport of Glyburide was carried out by Goldstein et
al demonstrating that Glyburide was a substrate of Pgp.167 As discussed earlier,
subsequent studies have repeatedly demonstrated that Glyburide is actively transported
by other ABC transporters, mainly BCRP and MRPs. As there are many studies with
BCRP and Glyburide, we chose to revisit the earlier Pgp transport of Glyburide, to
understand the substrate potential of the sulfonylurea class. The first part of our research
was to test the concentration dependence transport activity of Pgp using the MDCKMDR cell line. Glyburide, Glipizide, Glimepiride, Gliquidone, and Glisoxepide were run
in the transport assay, with concentrations varying from 2-100µM, and the apparent
permeability and subsequent ER were calculated at each concentration.
The four sulfonylureas showed carrier mediated transport activity as the rates of efflux
from the Pgp assay exceeded the rates of absorption for each Glyburide, Glimepiride,
Gliquidone, and Glisoxepide. These four analogs showed linear response in uptake and
efflux until the highest concentrations. At such high concentrations, the sulfonylureas
were acting as inhibitors and blocking their own up transport. This was expected as
Glyburide, Glipizide and Gliclazide have been reported as a Pgp inhibitor at high
concentrations. 168 Glipizide and Gliclazide, though structurally similar to the secondgeneration sulfonylureas, demonstrated no/slight Pgp activity and no BCRP activity in
our studies, with the rate of transport similar in both directions. It has also been reported
that both Glipizide and Gliclazide are Pgp substrates at high concentrations (100µM and
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500µM, respectively), but at the lower concentrations in our study, neither compound
was shown to have any Pgp or BCRP activity. 169
The second part of our research looked at the transport mediated activity of the series of
sulfonylurea analogs at a standard concentration of 2µM. The concentration was held
constant so as to identify the structure activity relationship and build three-dimensional
pharmacophore and QSAR models to explain the nature and character of the Pgp- and
BCRP-sulfonylurea interactions. The cell assays were performed for all available
sulfonylurea analogs, and the apparent permeability and subsequent ER were calculated.
The ER were then converted to log(ER) to use as the biological activity in the two and
three-dimensional QSAR models. The 45 compounds that showed Pgp activity and the 25
compounds that showed BCRP activity were used to build the respective pharmacophore
and QSAR models detailing the molecular attributes of the interaction.
The pharmacophore models demonstrated that the two main sections of the molecule, the
benzamido and aryl-sulfonylurea moieties, are key to explaining the interaction with both
Pgp and BCRP. In fact, in our study the molecules that lacked either substituent showed
no Pgp/BCRP activity. The pharmacophore model for each protein detailed 5 features
responsible for activity, with the models consisting of aromatics, 2 hydrogen acceptors, 1
hydrogen donor, and 1 hydrophobic group. The five-feature count was determined to be
the most appropriate value to use based on trial and error with the software program.
There was a balance of too few/too many features in the pharmacophore and still have a
model that represents the key points across the entirety of the molecule. The Pgp
pharmacophore consisted of two aromatic rings, two hydrogen acceptors and one
hydrogen donor. Meanwhile, the BCRP pharmacophore shared the aromatic and one
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hydrogen acceptor but differed in that there was only one hydrogen donator, with the
added feature of hydrophobic character on the benzamido ligand. The Pgp and BCRP
pharmacophore models are presented in Figure 29 as simple diagrams.

Figure 29. Simple diagrams of key pharmacophore features of the Pgp (left) and BCRP
(right) models, superimposed on the molecule Glyburide. Key: green aromatic, blue
hydrogen acceptor, red hydrogen donator, and orange hydrophobic.

Further evaluation of the sulfonylurea activities to the molecular structure through the 3D
QSAR models detailed the individual molecular features that add or subtract from the
observed Pgp or BCRP activity. Based on the sulfonylurea analog structures tested in our
work, the ligands attached at the far end of the aryl-sulfonylurea section of the molecule
appear to be less influential, as the structures can range from a simple alkane to complex
with multiple aromatic rings. Meanwhile, the ligands attached to the para position of the
arylsulfonylurea drive the activity of both Pgp and BCRP. Specifically, the benzamido is
needed for either activity; with the ligands attached to the ring also influencing the
activities. From our work, the ligands that increase the electron cloud are too hydrophilic
and decrease the activities. Conversely, the ligands that increase hydrophobic character or
maintain the electronics of the benzyl ring, maintain or increase the activities. A
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schematic representation of the core arylsulfonylurea attached to the benzamido ligand is
presented in Figure 30 with some example ligands that increase of decrease activity based
on our work.

Figure 30. Core structure of sulfonylurea with the potential ligands that can increase or
decrease the activity for both Pgp and BCRP. Note: light blue highlights benzamido
ligand; dark blue highlights arylsulfonylurea; blue circle denotes where bonding occurs
for ligands; and blue semi-circle denotes where bonding occurs for ligands.

The SAR of the sulfonylureas with the SUR1 receptor was first reported by Meyer et al
in 1999 and described the ligands on Glyburide that are required for SUR1 activity.
Meyer reported that removing the cyclohexyl or benzamido ligand marketed reduced
SUR1 activity. In fact, swapping the larger ring structures for smaller, less bulky groups
(i.e., methyl group) had the same effect. 170 This was also witnessed in our work, the
sulfonylureas that more closely resembled the Glyburide structure, containing the
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benzamido and aryl-sulfonylurea portions, were more likely to be substrates of Pgp and
BCRP. Similarly, if the sulfonylurea or analogs were missing one or the other benzamido
of aryl-sulfonylurea portion, then they were not recognized as Pgp or BCRP substrates.
Further, as demonstrated in the pharmacophore models, strategic placement of the
hydrogen donating/accepting, aromatics, hydrophobic, or bulky groups increased the Pgp
and BCRP activity.
Knowing that the sulfonylureas work through binding to the SUR1 protein (ABCC8),
which is also an ABC transporter protein like Pgp and BCRP, we looked to what is
known of the sulfonylurea and the target protein in the treatment of diabetes. The
sulfonylureas are designed to act on the SUR1 receptor, and therefore it would not be
controversial to propose that the same elements responsible for binding to the SUR1
receptor would also positively affect the interaction with Pgp or BCRP. This is exactly
what was determined by Bessadock et al. In fact, Bessadock performed a phylogenic
protein search of the ABC transporter proteins demonstrating that Pgp and SUR1 are
from the same protein cluster. Similarly, Vila-Carriles et al proposed that the SAR
driving the 2nd generation sulfonylureas has been to increase the binding affinity with the
sulfonylurea receptor, interacting with both the proposed A and B sites of the SUR
receptor, as shown in Figure 31. 171
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Figure 31. Representative binding sites on SUR1, tolbutamide and glyburide presented as
examples, reproduced from Vila-Carriles.

The second-generation sulfonylureas were designed to interact with both binding pockets
of the SUR1 protein, and in doing so were considerably more potent than the preceding
generation. This increased potency across the generations is the same impact as seen in
our work, in fact it mimics it very closely. Simply, those analogs that did not have both
the arylsulfonylurea and benzamido ligands did not exhibit Pgp or BCRP activity.
Building on the similarity of the SUR1 and Pgp transporter proteins theory, Bessadock et
al have reported the Glyburide pharmacophore based on the 3-dimensional alignment of
Glyburide with vinblastine, a known Pgp inhibitor. Their pharmacophore models called
out five key features: the two aromatic rings, two hydrogen donor groups (NH and NH
proximal to S), and one electron donor group (C=O) and is presented in Figure 30. Our
work is very much in line with these findings and confirms the Bessadock model. Also,
this model is representative of the hypothesized molecule features of the SUR1, which
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was expected based on the proximity on the ABC membrane transporter phylogenic tree.
172

Figure 32. Key features in Glyburide-Pgp interaction, reproduced from Bessadock. Key:
green is aromatic red is hydrogen donating, blue is hydrogen accepting groups.

We have found that pharmacophore model presented in Figure 31 accounts for many of
the same molecular features as reported in our research. We confirm the necessity of the
two aromatic rings, the two hydrogen donators, and the hydrogen acceptor. These
features are confirmed by the Pgp substrate activity of the 45 sulfonylurea molecules
used to build the pharmacophore.

CONCLUSION
Pgp and BCRP are the most studied ABC transporter proteins and have been found to be
largely responsible for the multidrug resistance phenomenon in cancer therapies, but
characterization of either has been difficult due to the lack of the membrane crystal
structure and general substrate promiscuity. Numerous groups are working towards
generating the crystal structure of the ABC transporters, but that work is still years to
come.173, 174 The lack of a defined substrate binding pocket for either Pgp or BCRP
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proteins has made it difficult to develop one single QSAR or pharmacophore model
describing the spatial and structural features responsible for activity. 175 However, as
demonstrated here, modeling transporter activity can aid in the understanding and general
knowledge of the drug-transporter interactions.
By using a large data set of sulfonylurea analogs representing the space of the oral
hypoglycemic compounds, we evaluated the substrate activity against to the ABC
transporter proteins Pgp and BCRP. This resulted in confirming the substrate activity for
41 analogs in the Pgp assay, and 25 analogs for the BCRP assay. Also, we have
demonstrated that Glimepiride, Glisoxepide, and Gliquidone are substrates of Pgp and
BCRP, all of which are previously unreported.
Our work has also confirmed the pharmacophore model previously presented in
literature, demonstrating that the sulfonylureas need certain 3-dimensional molecular
features to be substrates of Pgp and BCRP. Specifically, the benzamido and
arylsulfonylurea ligands are needed for both Pgp and BCRP activity. Furthering this
understanding, is the need for hydrogen donators/acceptors for Pgp activity, and the need
of hydrogen donators/acceptors and hydrophobic groups for BCRP activity. We also
found that the substituted benzamido ligand is important for both Pgp and BCRP activity,
with the ligand attached to the arylsulfonylurea not influencing the activities.
Computational QSAR models describing the Pgp and BCRP activity for a series of
sulfonylurea analogs were derived with statistical significance and predictive capabilities
by using the 2-dimensional and 3-dimensional molecular descriptors presented in the
VLifeMDS® suite. The predicative ability of these models observed for the training, test,
and validation sets of molecules make these models useful for designing new compounds
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to help explain sulfonylurea-Pgp and sulfonylurea-BCRP activity. Further, this is the first
set of QSAR studies performed to explain the ABC protein interactions of the
hypoglycemic sulfonylureas.
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COMPARISON OF PGP AND BCRP ACTIVITY FOR A SERIES OF
SULFONYLUREAS BY ACTIVITY CLIFF ANALYIS

ABSTRACT
Activity Atlas software was used to describe the protein activity between a series of
sulfonylureas and two of the ATP Binding Cassette (ABC) transporter proteins found
to be largely responsible for the active transport of Glyburide, Pgp and BCRP. The
Activity Cliff Analysis has provided a platform to understand the interactions that are
important to the guide the drug-protein interaction, with the potential to better design
medications for targeted delivery, for instance in pregnant women. The Activity Cliff
Analysis is based on the key features of average shape, hydrophobic region, and
electrostatic patterns of the active compound, and were mined and mapped to detail
the differences in molecular features driving the ABC protein activity to either Pgp or
BCRP, specifically.
As described in our previous work, Activity Atlas was used on a large series of
sulfonylurea analogs, with the objective of investigating and understanding the
molecular features that underlie the ABC protein activity in the hopes of better design
of pregnancy centered medications. As expected there were many similarities in the
molecular features driving the protein-sulfonylurea activity; but there were also many
appreciable differences as demonstrated by the analysis of the hydrophobic,
electrostatic and shape molecular descriptors. When coupled to the 3D QSAR data, the
Activity Atlas method is particularly useful to visualize and decipher structure activity
relationships.
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INTRODUCTION
Glyburide is a second-generation sulfonylurea used in the treatment of Type II
Diabetes and has been shown to be especially effective in patients that retain some
level of insulin production from the pancreatic beta cells. As outlined in the Chapter 1
Introduction section, researchers began looking to Glyburide as a treatment option for
gestational diabetes mellitus (GDM). The similarities in the pathophysiology of type II
and GDM make the oral hypoglycemic agents a smart choice, as compared to insulin.
In fact, researchers have run numerous clinical studies demonstrating that Glyburide is
as safe and efficacious in pregnant women as insulin, without many of the insulin
related difficulties.
It is in these studies of Glyburide with GDM that researchers have determined a
unique placental transport activity. Specifically, Glyburide has been demonstrated to
not cross the placental barrier to any appreciable effect; and, Glyburide will leave the
fetal compartment against the concentration gradient. 176, 177 Numerous studies have
been performed to understand the mechanism responsible, and it has been found that
Glyburide is actively transported by the ATP binding cassette (ABC) transporter
proteins, specifically Pgp, BCRP and the MRPs. 178, 179, 180, 181, 182, 183

The ABC

proteins are responsible for the active transport of endogenous and exogenous
molecules at the barrier membranes throughout the body and have been shown to be
important players in the pharmacokinetic profiles and disposition of many drugs.
The documented interactions of Glyburide with the ABC transporter proteins have
prompted numerous studies evaluating Glyburide, Glipizide, and Gliclazide, with
similar results. 184 In these studies Glyburide, Glipizide, and Gliclazide have been
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shown to act as substrates or inhibitors of the ATP transporter proteins, depending on
the concentration dosed. 185, 186, 187 Figure 32 shows the molecular structure of the
three sulfonylureas most studied with the ABC transporters.

Figure 33. Glyburide, Glipizide, and Gliclazide structures.

Many studies have been also performed to understand the placental transport,
pharmacokinetics/pharmacodynamics, or even to determine the proteins responsible
for the transport of Glyburide. Our research is the first investigation to study the
interaction of the sulfonylurea hypoglycemic agents and the ABC transporter proteins.
In this investigation, a series of sulfonylurea analogs were studied for activity against
Pgp and BCRP in cell-based transport assays. From the transport assay data, we used
Cressets Activity Atlas modeling capabilities to identify and describe the key
molecular features of the sulfonylurea analogs driving the interaction with either the
Pgp or BCRP. Understanding the differences in the molecular targets could have a
profound impact on tailored drug delivery and the future of medicine. Specifically,
these studies may contribute to the design of medications for pregnant women that are
safe and efficacious, without presenting any harm to the fetus.
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DATA SET
A total of 78 sulfonylurea analogs were available to be evaluated in the Pgp and BCRP
cell-based transport assays. For the Pgp assay, all 78 compounds were tested, with a
subset of 53 compounds tested in the BCRP assays. The transport assays were
performed in Madin-Darby Canine Kidney cells that were transfected with
overexpressing Pgp or BCRP genes. The transport assays were validated with positive
and negative transport control compounds, and the cell-monolayers determined
acceptable for use by measuring the trans-epithelial resistance, as discussed in the
preceding chapters. As our research and published articles have shown, Glyburide has
been reported as a substrate for both Pgp and BCRP, and as a substrate and/or
inhibitor for other ABC transporters and was therefore used as the reference molecule
in the studies. As a crystal structure of the sulfonylureas with either protein has not
been reported, the lowest energy conformation was used in these studies as described
by Lins et al. 188 The lowest energy conformations were determined with by
Chemaxon® and ChemDraw® software using the MMFF94 energy minimization
calculation algorithms. 189, 190
The sulfonylurea analogs were tested at a constant concentration (2µM) as per internal
procedure, with each measurement performed in at least triplicate to assure adequate
statistical control. The data generated from each cell-based assay was then used to
build 2D and 3D quantitative structure activity models (QSAR) and a pharmacophore
model with the molecule design software suite from VLifeMDS. The 2D and 3D
QSAR models demonstrated excellent predictability, but for the work presented here,
we will focus on the 3D data set and modeling. For both cell-cased assays, the 3D
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protein models demonstrated excellent predictability with the Pgp model
demonstrating a linearity value of r2 = 0.8304 and cross-validation of q2 =0.7501; and
the BCRP model demonstrating a linearity value of r2 = 0.9083, with a crossvalidation value of q2 = 0.7789.

CONFORMATION HUNT AND ALIGNMENT OF MOLECULES
The first step of the modeling efforts was to generate the most stable conformations
and to overlay the molecules to a template. As Glyburide is well characterized and
known to interact with Pgp and BCRP, we used Glyburide as the template molecule
for conformer hunting and molecular alignments. The conformation hunt was carried
out with Cresset Forge® software package using the MMFF94 energy minimized
structure of Glyburide, as we have previously reported. 191 The remaining sulfonylurea
analogs were aligned by the maximum common substructure, using the “very accurate
but slow” configuration setting to maximize success. The details of the conformation
hunt parameters are:

Max Number of conformations 1000
RMS cutoff for duplicate conformers: 0.5
Gradient cutoff for conformer minimization: 0.1kcal/mol
Energy window: 3kcal/mol

As with all 3D model generation, the molecular alignment is the most critical first step
and if not performed correctly can lead to incorrect modeling practices. After
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completion of the alignment process, visual inspection of the all the molecular
alignments was performed to make sure there were no disparities between molecules.
The molecules were evaluated for maximal alignment scores against Glyburide and
the molecules that were suboptimal, were adjusted and rescored. For example,
manipulating the phenyl ring of the benzamido substructure proved to be the most
common fix, and maximized the substructure similarity scores to Glyburide.

ACTIVITY ATLAS MODELING
The Activity Atlas modeling is part of the Cresset Forge® molecular dynamics
software package and is routinely used for the design and discovery of new molecules.
The Activity Atlas modeling suite performs three types of analyses that are key to the
understanding the activity for the molecules against a specific target, and are defined
as the Average of the Actives, Activity Cliff Summary, and the Regions Explored
Analysis. 192 For our research, the Regions Explored analysis was not performed as it
is an assessment of what regions have been explored on the molecule, disregarding the
biological activity. For the research performed here, we will discuss the Average of
Actives and Activity Cliff Analysis, as they will have more insight on the activity of
the sulfonylureas.
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ACTIVITY CLIFF MODELING
As described in the literature references, Activity Analysis modeling can pinpoint the
critical region of the structure activity relationships (SAR), providing a visual
summary of the activity cliff for each of the data sets. 193 An Activity Cliff is defined
as a pair or series of structurally similar compounds that have a large difference in
potency or activity.194 This is especially pertinent for sets of molecules run in different
assays, allowing the data to be combined and compared to further characterize the
molecules, the associated biological activity and critical differences in SAR.
As discussed by Cheesewright et al., describing how the molecule fits into a binding
pocket requires the ability to define the properties near the molecular surface, and not
simply as a collection of atoms. 195 Normally, this modeling effort would be too
calculation-intensive with long computer run times. The benefit of the Cresset
software to simplify and this process and condense the complex three-dimensional
fields (for example, electrostatic and van der Waals) down to local extrema, called
field points. These field points are defined for key molecular features, such as H+
donor, H+ acceptor, positive/negative ionic character, hydrophobic character, etc. The
field points are then grouped into field patterns, with these field patterns able to
compare molecules directly, representing a summary of the 3D properties of each
molecule.
In order to evaluate the molecular features against a given biological activity, a 3D
lattice of grid points is created covering the entire volume surrounding the molecule.
For each point or each pair of points, a coefficient is then created to define the space.
The calculation for each coefficient is calculated by:
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Coeff = (disparity-minDisparity) * ∆Fieldxyz * weight
Where Coeff is the grid point
Disparity is the value between two molecules
MinDisparity is a minimum threshold value
∆Fieldxyz is the field difference at this point described for this
molecular pair
Weight is the product of the molecule and alignment weights

The calculation for the coefficient represented in the above equation helps pinpoint the
critical regions of the structure activity relationship by looking at each grid point in
relation to the others.

AVERAGE OF ACTIVES MODELING
The Average of Actives Analysis Model describes the common attributes that the
active molecules in the data set have in common. This calculation is performed for all
field points and at each grid point surrounding the molecules. Building on the Activity
Cliff modeling, the Average of Actives is a summary of the Activity Cliff modeling
and also creates a 3D lattice of grid points of the lattice surrounding the aligned
molecules and calculates a coefficient. The coefficient for the Average of Actives
modeling is calculated according to the equation 196:
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Coeff = Fieldxyz * Weight
Where Coeff is the coefficient for the grid point
Fieldxyz is the field at the grid point for the active molecule
Weight is the product of the molecule and alignment weights

RESULTS
The results of the Activity Cliff Analysis show distinct difference between the
sulfonylurea analogs interactions with ABC transporters, Pgp and BCRP. To ensure
robust calculations, the molecules were energy minimized using the MMFF94 energy
field, and then conformer generation was performed to ensure the molecular structure
disparity was minimized to eliminate variability and allow for the modeling to be
governed only by the biological activity of the aligned structures.
In performing the comparative analysis differentiating the model systems, we
compared the BCRP activity data against the Pgp activity data (Figure 2). As shown in
the Figure, there is good correlation between the Pgp and BCRP activity, with a
linearity score of 0.84 This correlation shows that the nature of transport for the two
proteins is similar, with more sulfonylurea analogs substrate of Pgp than that of
BCRP, as shown by the activity. This proved a very interesting point as the
understanding was that Glyburide (and by assumption, the sulfonylurea class) would
show more substrate activity with BCRP, as is reported in literature. 1-8 The activity
map detailing the Pgp activity to that of BCRP is shown in Figure 34.
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Figure 34. Activity map of the sulfonylurea analogs tested in the Pgp and BCRP efflux
assays.

Also shown in the Pgp and BCRP activity map in Figure 33 there are three regions
that describe the activity of the sulfonylurea analogs and the Pgp and BCRP
transporter proteins. For reference, Glyburide is the red dot in the center of the graph
(data points 0.45 BCRP and 0.8 Pgp) and splits the activity data into three distinct
categories: Pgp/BCRP activity less than Glyburide, Pgp/BCRP activity similar to
Glyburide, and Pgp/BCRP activity greater than Glyburide. The molecules with Pgp
and BCRP activity less than Glyburide are straightforward to explain as the molecules
in this group are smaller in molecular weight and, in the preponderance of cases, lack
the large, lipophilic benzamido ligand. This point is important as it has been shown
that the first-generation sulfonylureas that are smaller, and less hydrophobic do not
interact with the ABC transporter proteins as the second generations sulfonylureas
have been shown to do. 197 The analogs that have Pgp/BCRP activity similar to
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Glyburide are similar in structure, molecular weight, and ligand placement, and
therefore will behave in a like manner, as expected. The third region is those
molecules that have increased Pgp/BCRP activity as compared to Glyburide, which
can be due to change in the physical-chemical properties of the molecules, such as
molecular weight, lipophilicity, etc.
As previously reported by our lab, the pharmacophore of the sulfonylurea-Pgp and the
sulfonylurea-BCRP systems demonstrated different feature points, as shown in Figure
3. A simple definition of the pharmacophore model is a representation of the steric and
electronic features that are necessary for the interaction with a protein or a biological
response. For both of the pharmacophores, the feature points were spread throughout
the entire molecule, outlining the areas of interest. As shown in Figure 3, there are
four feature points that are similar in both pharmacophores, with two distinct
differences. The differences in the Pgp and BCRP pharmacophore models were found
to be at the amide and benzamido ring moieties, respectively. For reference, the fivepoint pharmacophores describing the Pgp and BCRP protein interactions with the
sulfonylureas are presented in Figure 35.

Figure 35. Pharmacophore Models detailing Pgp (left) and BCRP (right) features.
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The 3D QSAR modeling of drug-protein interactions is also very important to help
understand the similarities and differences of the two protein models. As we have
previously demonstrated, the 3D QSAR models identify the molecular features
responsible for the activity in the space surrounding the molecules. As shown in
Figure 4, the electrostatic and steric field points (blue and green spheres, respectively)
of each model are shown overlaid on the most active commercial sulfonylureas
(Glyburide, Glimepiride, Glisoxepide, Gliquidone, and Glipizide). As discussed in the
previous chapters, these field points and their corresponding charges aid in the
understanding of key molecular features but are limited in explaining the activity in
the 3D space.

Figure 36. 3D field points describing model space for Pgp (left) and BCRP (right)
Pharmacophores.

The Activity Cliff analysis presented in the Cresset Forge® software module provide
3D visualizations of a molecule set giving clear indications about the electrostatic,
hydrophobic, and shape features. Taking into account bot pharmacophore and 3D
QSAR models, the Activity Cliff Analysis was performed to further characterize the
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sulfonylurea and Pgp/BCRP affinity. This comparison gives insight into the molecular
attributes influencing the Pgp or BCRP substrate-interaction selectivity. The 3D
molecular maps of the Activity Cliff Summary describing the activity for the
sulfonylurea analogs are shown in Figure 37.
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Figure 37. Activity cliff summary maps describing the sulfonylurea-Pgp (top) and
sulfonylurea-BCRP (bottom) activity.

Starting with the Activity Cliff Summary maps, we will describe the molecular
features needed for each interaction to improve the selectivity of the sulfonylurea
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analogs for Pgp or BCRP. As shown in the activity summary maps in Figure 5, there is
a good deal of overlap in the electrostatic, hydrophobic, and shape molecular
descriptors. However, there is also differences specific to each Pgp and BCRP model
that can explain the subsequent interaction. For both sets of sulfonylurea-protein
interactions, there are specific parts of the molecule that play an important role
regardless of the model. The benzamido, cyclohexyl, and aryl sulfonylurea ligands
play an important role for the Pgp and BCRP activity. For further clarity, each of the
modeling summary maps will be individually explained, along with the individual
summary maps presented in the following sections, and in Figures 38, 39 and 40.
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ELECTROSTATICS AVERAGE SUMMARY

Figure 38. Summary of electrostatics activity for sulfonylurea interaction with Pgp
(top) and BCRP (bottom).
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The electrostatics average summary explains where an increase in negative (red) or
positive charge (blue) will increase activity. As presented in Figure 6, the
electrostatics summary details the differences in the sulfonylurea interactions needed
for the Pgp and BCRP proteins. As shown in Figure 37. there are some pronounced
differences in the results for the negative and positive electrostatic effects of the
protein-molecule interaction. For the sulfonylurea-Pgp interaction, there is a mix of
positive and negative charges that influence the activity, encompassing the top portion
of the sulfonylurea moiety, and surrounding the carbonyl and methoxy groups on the
benzamido moiety. There is also a slight positive effect needed around the two amides
of the sulfonylurea moiety. This is different for the sulfonylurea-BCRP interaction has
an overwhelming positive charge that governs the ligand-protein interaction. This
positive charge needed for an increase in activity covers the cyclohexyl ring, across
the sulfonylurea to the central phenyl ring all the way surrounding the carbonyl and
methoxy groups of the benzamido moiety.
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HYDROPHOBICS AVERAGE SUMMARY

Figure 39. Summary of hydrophobics activity for sulfonylurea interaction with Pgp
(top) and BCRP (bottom).
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The hydrophobics average summary explains where an increase in hydrophobic
character will increase or decrease the activity and is described as favorable (green) or
unfavorable (purple) hydrophobics. As shown in Figure 39, there is some overlap of
the hydrophobic character between the two models. For the Pgp model, there is
favorable hydrophobic activity surrounding the entire cyclohexyl ring, the amine,
chloro, methoxy, and phenyl ring of the chlorine on the benzamido moiety. However,
there is a small unfavorable hydrophobic activity around the two carbons of the phenyl
ring between the methoxy and chloro moieties. For the BCRP model, there is
favorable hydrophobic activity on the farthest carbon atoms of the cyclohexyl ring,
surrounding the amide group and the chloro group of the benzamido moiety.
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SHAPE SUMMARY

Figure 40. Summary of shape activity for sulfonylurea interaction with Pgp (top) and
BCRP (bottom).
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The shape summary explains where bulky groups are needed to increase the activity
and is described as favorable (green) or unfavorable (purple) shape. As shown above
in Figure 40, the shape summary details the differences in the sulfonylurea interactions
of the Pgp and BCRP proteins. For the Pgp model, there are mostly favorable shape
descriptors, with two main areas demonstrating unfavorable shape. The favorable
shape surrounds the cyclohexyl ring, the sulfonyl and carbonyl moieties, and the larger
feature of the amide, methoxy and chloro of the benzamido ligand. The unfavorable
shape occurs between the amides and carbonyl of the sulfonylurea moiety. For the
sulfonylurea- BCRP interaction, there are mostly favorable shapes, encompassing the
outer ring moieties. Moving from left to right in the depiction above, there are two
large areas of favorable shape on the bottom half of the cyclohexyl ring through the
carbonyl of the sulfonylurea, and on the top half of the molecule, surrounding the
amide, methoxy and chloro moieties of the benzamido ligand of the molecule.

DISCUSSION
The ABC transporter proteins are responsible for the active transport of substrates into
and out of cells. Specifically, ABC transporter proteins have gained much notoriety
for being responsible for the multidrug resistance (MDR) phenomenon in various
cancer treatments. 198 Much work has been done over the years to identify the features
of a molecules that are responsible for inducing interactions with the ABC efflux
transporters.199 Expanding on that research, many groups have looked to develop
global models that will identify the universal features of molecules that are substrates
or inhibitors. 200 However, this has proven very elusive as the broad substrate
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specificity of each of the transporters proteins allows for much overlap for the
substrate recognition. From a biological standpoint, the overlap of substrate
recognition is needed and very much an inherent part of the body’s redundant system
of protection. 201 202
With this is mind, we endeavored to describe the interaction of a single class of
compounds, the sulfonylureas, with two prominent ABC transporters, Pgp and BCRP.
In order to decipher the underlying structure activity relationship of the sulfonylurea
and ABC transporter proteins, the molecules’ transporter activity was examined by the
Activity Analysis Cliffs for the electrostatic, hydrophobic, and shape descriptors. The
first step in this process was to generate the lowest energy conformers, and then
overlay the molecules on the template molecule, Glyburide. This allowed for the
activity to be solely a function of the molecular structure, and for the generation of
field points surrounding the molecules. These field points were then used for the
visualization and calculation of the Activity Cliff data describing each sulfonylureaprotein interaction.
Results of the Activity Cliff analysis study detail many similarities governing the
activity and interaction between the sulfonylureas and the ABC transporters, Pgp and
BCRP. To start, the central aryl ring serves as a linker to the benzamido and
sulfonylurea ligands and does not contribute to the transporter activity calculation.
There is electrostatic activity in both models surrounding the sulfonylurea and
carbonyl group. Also, there is a good deal of overlap between the models on the
favorable shape on activity surrounding the cyclohexyl and benzamido ligands. The
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hydrophobic summary also details very similar activity surrounding the cyclohexyl
and benzamido ligands of both models.
Though the sulfonylurea-protein models are very similar in many of the electrostatics,
hydrophobics and shape character, there are still some obvious differences. The
electrostatics Activity Cliff Analysis surrounding the sulfonylurea and carbonyl
ligands present differently in each model. The BCRP model requires more positive
charges surrounding the entire molecule, at the sulfonylurea in its entirety, around the
far side of the central aryl ring, and on the carbonyl of the benzamido ligand. This
contrasts with the Pgp model which has a mix of negative and positive charges
governing activity; negative charge around the sulfonylurea and benzamido carbonyl,
and positive charge surrounding the amides of the sulfonylurea. To describe the
structure activity relationship for electrostatics descriptor, having more negative
groups at these locations on the molecule will increase Pgp activity and decrease the
BCRP activity.
For the shape activity analysis model there are some considerable differences
governing the activity for each model. There is a much larger area surrounding the
molecule in the BCRP model that requires an increase in bulky groups as compared to
the Pgp model. The BCRP model has favorable bulky groups covering the entire
cyclohexyl and benzamido ligands. In contrast, the Pgp model has scattered favorable
bulky groups on the cyclohexyl and sulfonylurea ligands, with a similar though
slightly smaller favored bulky group surrounding the amide and back side of the
substituted phenyl ring. To describe the structure activity relationship for the shape
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descriptor, having bulky groups on the cyclohexyl favors the BCRP activity, whereas
having bulky groups on the benzamido ligand would benefit both models’ activity.
For the hydrophobic Activity Analysis model there is a great deal of similarity, with
only a few small discrepancies governing the activity. The BCRP model has favorable
hydrophobic character on the far side of the cyclohexyl ring, and above the amide
ligand. In contrast, the Pgp model has favorable hydrophobic character surrounding
the whole cyclohexyl group, and surrounding the entire benzamido ligand, wrapping
the upper section of the molecule. To describe the structure activity relationship for
the hydrophobics descriptor, increasing the hydrophobic character surrounding the
benzamido ring would benefit the Pgp activity, whereas increased hydrophobic
character on the amide and cyclohexyl ring would benefit both Pgp and BCRP
activity. A summary of the learnings from the electrostatic, hydrophobic, and shape
activity atlas analysis are presented in Figure 41.

Figure 41. Summary of Activity Atlas modeling for the Pgp and BCRP models on
Glyburide.
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The Activity Atlas Modeling has proven to be a valuable tool for deciphering the
structure activity relationships defining the interactions of sulfonylurea analogs with
Pgp and BCRP transporter proteins. Using the Activity Atlas modeling we were able
to leverage the three-dimensional insight for a series of sulfonylureas and the
associated Pgp/BCRP activity, based on electrostatic, hydrophobic, and shape
descriptors. This led to identifying key molecular features that were missed in our
previous modeling attempts. The Activity Atlas modeling specifies the need for bulky
steric groups, an increase in hydrophobic character, and more positively charged
groups on/near the cyclohexyl ring. Also, the Activity Atlas model specifies the need
for increased hydrophobic character and bulky steric groups on the benzamido moiety.
Finally, and representing the difference in activity between the two proteins, the space
immediately surrounding the sulfonylurea and amide groups require different charges
to drive the activity, with an increase in negative charge increasing the Pgp activity,
and an increase in positive charge increasing the BCRP activity.

CONCLUSION
This is the first summary and comparison of a large series of sulfonylurea analogs
activity with the ABC transporter proteins, Pgp and BCRP. Based on the work
previously reported on Glyburide and its unique placental transport activity, we sought
to define the molecular properties responsible for interaction with the ABC
transporters in the hopes of learning how to use this information to better design
pregnancy centered medications. The sulfonylurea analogs tested in our work show a
higher propensity for Pgp activity as compared to that of BCRP. This means that in
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our cell-based transport assays, the same molecule had higher activity in the Pgp
model than in the BCRP model. As the cell-based assays are very sensitive to drug
concentration effects, we maintained drug concentrations to that were carefully
selected to not elicit a false positive or negative response.
Applying the understanding from the activity cliff analysis, the 3D QSAR models
generated were condensed down to a simple map of the critical points driving the
structure activity relationship for three descriptors: electrostatics, hydrophobics and
shape. The Activity Cliff Analysis detailed key similarities and differences governing
the molecular features driving activity in the Pgp and BCRP protein models. Though
the electrostatic, hydrophobic, and shape activity cliffs were shared across molecules
in both models, there are important differences in that could be used to drive the
sulfonylurea interaction to Pgp or BCRP. In this regard, the Activity Atlas modeling
proved to be a valuable tool as previously undiscovered features were characterized
and shown to be of key importance to define the sulfonylurea-Pgp/BCRP activity.
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Designing Pregnancy Centered Medications: Insights and Recommendations
The first three chapters detail the evaluation of a series of sulfonylurea analogs in cellbased transport assays to determine if they are substrates for the ATP binding cassette
transporter proteins, Pgp and BCRP. The cell lines used in the study were MadinDarby Canine Kidney cells, stably transfected for Pgp or BCRP gene overexpression,
described and characterized in literature and summarized in Chapters 1 and 2.
Glyburide is the most prescribed oral sulfonylurea medication and has been shown to
be actively transported by the ABC transporter proteins, specifically Pgp and BCRP,
but also by various other transporters. Our work examined the interaction of the
sulfonylurea analogs with Pgp and BCRP, and determined the molecular features
driving the specific protein activity. We confirmed that the sulfonylureas are
substrates of both Pgp and BCRP and built pharmacophore and QSAR models
explaining the Pgp and BCRP activities in the two and three-dimensional space.

The study of Glyburide and the ABC transporters has presented a unique and exciting
opportunity to learn about tailoring drug delivery for pregnant women. As discussed
previously, Glyburide has demonstrated unique placental transport due to the active
transport by the ABC transporters, minimally crossing the placenta and leaving the
placenta against the concentration gradient. The treatment of Gestational Diabetes
Mellitus with Glyburide is an interesting case for drug delivery to the receptor
(pancreatic β-cells), allowing the mother to maintain and control insulin levels for
proper function, while limiting the exposure of the drug to the fetus (through placental
transport). Numerous studies have been performed to evaluate the pharmacokinetics
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and pharmacodynamics of Glyburide during pregnancy detailing: the fetal exposure,
umbilical cord concentrations, the safety compared to insulin, and placental transport
assays. However, there has not been extensive research to understand the molecular
properties responsible for driving the interaction with the ABC transporters
responsible for the placental transport, for instance, with Pgp instead of BCRP.

Our research demonstrated that the sulfonylurea molecules need to have specific
physical-chemical parameters to have ABC transporter activity, in Pgp and BCRP.
These parameters, among many others, speak to the size, shape, and lipophilicity of
the molecule, governed by the placement of ligands at the appropriate locations on the
molecule. As discussed in chapters 2 and 3, the sulfonylurea analogs with similar or
larger molecular weight or molecular volume as compared to Glyburide were more
likely to be substrates for both Pgp and BCRP. Conversely, sulfonylurea analogs that
were much smaller in molecular weight and volume, or were missing the
arylsulfonylurea and benzamido core structure, were not substrates of either Pgp or
BCRP. We found that these results were consistent with the structure activity
relationship of the first and second-generation sulfonylureas, with the smaller, firstgeneration sulfonylureas being weak substrates of the SUR1 receptor. The main
difference between the fist and second-generation sulfonylureas lies in the “core”
structure found to increase potency of the second-generation sulfonylureas. This
required core structure is presented in Figure 42, with the benzamido ligand
highlighted in light blue, and the arylsulfonylurea highlighted in dark blue.
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Figure 42. Diagram of core structure for each sulfonylurea generation highlighting the
arylsulfonylurea (dark blue) and the benzamido (light blue) ligand.

Based on the Activity Cliff modeling reported in Chapter 3, our research has shown
that adding ligands to increase the hydrophobicity and steric hinderance (bulky
groups) to the substituted benzamido ring and to the amide ligand of the aryl
sulfonylurea sections of the molecule increase the activity for both Pgp and BCRP.
Also, we have shown that increasing the positive charge on the cyclohexyl ligand
attached to the arylsulfonylurea also increases activity for both Pgp and BCRP. We
found the differences in the Pgp or BCRP activities were connected to two locations
on the Glyburide molecule: the sulfonylurea and amide moieties on either side of the
central aryl ring. Specifically, that an increase the positive charge or negative charge at
these specific locations (figure 43), would make the molecules more likely to be
BCRP or Pgp substrates, respectively.
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Figure 43. Summary of Activity Atlas modeling for the Pgp and BCRP models on
Glyburide. Note: blue circles indicate the key feature placement behind the activity
differences in each model.

Based on this work presented in chapters 1-3, we present some recommendations to
design medications for pregnant women based on these learnings from our Glyburide
case study. First, and assumed, the molecules need to have appropriate safety and
PK/PD parameters, for example, high protein binding (>99%), high bioavailability
(80-100%), moderate half-life (4 to 10hrs), to afford predictable and well-behaved
ADMET (absorption, distribution, metabolism, excretion, toxicology) properties.
Similarly, important physical-chemical properties would warrant the molecules to be
at least the same size (Mw of ~500g/mol), volume (molecular vol 424.74), and
molecular shape (low energy conformer in Figure 44) to interact with binding pockets
of the target receptor (in this case, SUR1), as well as the placental ABC transporter
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proteins. Specifically, those molecules fitting the Glyburide pharmacophores need an
increase in the bulky and hydrophobic ligands on the ends of the molecule, with
strategically placed electrostatic groups (negative or positive) in the central core to
enhance the ABC transporter activity. Designing molecules that incorporate these
molecular features, aligned against the Glyburide pharmacophore for Pgp or BCRP,
will increase the respective activity. The preceding are all learnings from our research
to direct the sulfonylurea molecules to interact with one protein or the other.

Figure 44. Glyburide low energy conformation used in our research.

For the purpose of keeping drugs out of the placenta, interactions with more than one
ABC transporter protein would provide a potentially superior solution. For conditions
requiring treatment in transporter rich areas, for example the blood brain barrier, this
approach will not work due to the need to cross the tight junctions containing the
numerous transporters designed for redundant protection. However, for those disease
states that have receptor targets outside of the area protected by the ABC proteins, this
approach may be appropriate. Therefore, to design pregnancy centered medications,
we need to maintain the fetal protection by designing the molecules that interact with
numerous placental transporters. This would allow for protection of the fetus by the
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natural and redundant system of the ABC Transporter proteins, inherent in pregnant
women and ever increasing over the course of gestation. By design, the molecules
would interact with more than one ABC transporter, allowing for redundant protection
of the fetus if an issue arose with one of the transporters in the mother, for example,
Pgp deficiency or mutation in the BCRP protein reducing the activity.
To better define this idea, future research efforts will focus on evaluating the substrate
activity of the sulfonylurea analogs in other ABC transporter proteins known to be
present in the fetal-placental barrier.
Following the work presented in this thesis, the two and three-dimensional QSAR
models would be built for the new sulfonylurea-ABC protein interactions, and the
respective pharmacophores generated. Aligning the pharmacophore models of each
ABC transporter against the lowest energy conformation of Glyburide will allow for
the overlap the key points from each molecule to the overall key pharmacophore
features. Then, comparing the numerous models against each-other in the Activity
Analysis software will help describe the needed features for each interaction. And
finally, this concept will be tested in a more “global mode”, using our sulfonylurea
activity models to predict and describe the key pharmacophore features and activities
of other molecular classes.
As you can imagine, the treatment options for pregnant women is severely limited due
to the fact that most drugs will cross the placenta and present a safety risk to the fetus.
Therefore, designing drugs not to cross the placenta would allow doctors to treat
pregnant women’s conditions without harming the fetus. This would expand the
treatment options and positively impact the lives and conditions of an entire subset of

115

the population currently overlooked, with the potential to revolutionize treatment
options.
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APPENDIX I
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Number
1

Structure

BCRP
Papp

log BCRP
Papp

2.78
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